var title_f9_37_9808="Pheochromocytoma silent";
var content_f9_37_9808=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pheochromocytoma silent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abdominal CT showing an 8-cm left adrenal mass (arrow) discovered incidentally. Note the vascular and inhomogenous imaging characteristics of this mass. Biochemical evaluation was consistent with a clinically silent pheochromocytoma, which was confirmed at surgery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William F Young, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_37_9808=[""].join("\n");
var outline_f9_37_9808=null;
var title_f9_37_9809="Candida albicans vaginitis";
var content_f9_37_9809=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candida albicans vaginitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 248px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power micrograph of hyphal elements seen on 10 percent KOH examination of a patient with",
"    <em>",
"     C. albicans",
"    </em>",
"    vaginitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jack D Sobel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_37_9809=[""].join("\n");
var outline_f9_37_9809=null;
var title_f9_37_9810="Severe upper airway obstruction in children";
var content_f9_37_9810=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Management of severe upper airway obstruction in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 761px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ORL: otolaryngologist; OR: operating room.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_37_9810=[""].join("\n");
var outline_f9_37_9810=null;
var title_f9_37_9811="Weight loss surgery";
var content_f9_37_9811=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Weight loss surgery (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/37/9811/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/37/9811/contributors\" id=\"au3538\">",
"       Robert A Andrews, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/37/9811/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/37/9811/contributors\" id=\"se3537\">",
"       Daniel Jones, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/37/9811/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/37/9811/contributors\" id=\"de3439\">",
"       Rosemary B Duda, MD, MPH, FACS",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?9/37/9811?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      WEIGHT LOSS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Bariatric surgery (from the Greek words \"baros,\" meaning \"weight,\" and \"iatrikos,\" meaning \"medicine\") is the term for a surgery that is done to help you lose weight. Bariatric surgery is not recommended for everyone who is overweight or obese. However, it may be an option if you are obese and have not been able to lose weight with other methods.",
"    </p>",
"    <p>",
"     A person is categorized as underweight, healthy weight, overweight, or obese based on his or her body mass index (BMI). Body mass index is a way to measure body fat that is based on your height and weight (",
"     <a class=\"calc calc_patient\" href=\"UTD.htm?41/23/42366?source=see_link\">",
"      calculator 1",
"     </a>",
"     and",
"     <a class=\"calc calc_patient\" href=\"UTD.htm?36/47/37630?source=see_link\">",
"      calculator 2",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A BMI of 25 to 29.9 is considered overweight",
"      </li>",
"      <li>",
"       A BMI of &ge;30 is considered obese",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This article will focus on surgery for obesity. Nonsurgical weight loss is reviewed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information about surgical weight loss is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"      \"Surgical management of severe obesity\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SHOULD I HAVE SURGERY TO LOSE WEIGHT?",
"     </span>",
"    </p>",
"    <p>",
"     Weight loss surgery is recommended",
"     <strong>",
"      ONLY",
"     </strong>",
"     for people with one of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Severe obesity (body mass index above 40) (",
"       <a class=\"calc calc_patient\" href=\"UTD.htm?41/23/42366?source=see_link\">",
"        calculator 1",
"       </a>",
"       and",
"       <a class=\"calc calc_patient\" href=\"UTD.htm?36/47/37630?source=see_link\">",
"        calculator 2",
"       </a>",
"       ) who have not responded to diet, exercise, or weight loss medicines",
"      </li>",
"      <li>",
"       Body mass index between 35 and 40, along with a serious medical problem (including diabetes, severe joint pain, or sleep apnea) that would improve with weight loss",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     You should be sure that you understand the potential risks and benefits of weight loss surgery. You must be motivated and willing to make lifelong changes in how you eat to reach and maintain a healthier weight after surgery. You must also be realistic about weight loss after surgery (see",
"     <a class=\"local\" href=\"#H9\">",
"      'Effectiveness of weight loss surgery'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PREPARING FOR WEIGHT LOSS SURGERY",
"     </span>",
"    </p>",
"    <p>",
"     Most people who have weight loss surgery will meet with several specialists before surgery is scheduled. This often includes a dietitian, mental health counselor, a doctor who specializes in care of obese people, and a surgeon who performs weight loss surgery (bariatric surgeon). You may need to work with these providers for several weeks or months before surgery.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The nutritionist will explain what and how much you will be able to eat after surgery. You may also need to lose a small amount of weight before surgery.",
"      </li>",
"      <li>",
"       The mental health specialist will help you to cope with stress and other factors that can make it harder to lose weight or trigger you to eat",
"      </li>",
"      <li>",
"       The medical doctor will determine whether you need other tests, counseling, or treatment before surgery. He or she might also help you begin a medical weight loss program so that you can lose some weight before surgery.",
"      </li>",
"      <li>",
"       The bariatric surgeon will meet with you to discuss the surgeries available to treat obesity. He or she will also make sure you are a good candidate for surgery. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"        \"Patient information: Sleep apnea in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Starting a serious exercise program prior to surgery will help you prepare mentally and physically for surgery, help you reduce weight prior to surgery, and allow you to have a program you might continue after you recover.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      TYPES OF WEIGHT LOSS SURGERY",
"     </span>",
"    </p>",
"    <p>",
"     There are several types of weight loss surgeries, the most common being lap banding, gastric bypass, and gastric sleeve (",
"     <a class=\"graphic graphic_table graphicRef73045 \" href=\"UTD.htm?5/27/5565\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Lap banding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Laparoscopic adjustable gastric banding (LAGB), or lap banding, is a surgery that uses an adjustable band around the opening to the stomach (",
"     <a class=\"graphic graphic_figure graphicRef66685 \" href=\"UTD.htm?0/2/39\">",
"      figure 1",
"     </a>",
"     ). This reduces the amount of food that you can eat at one time.",
"    </p>",
"    <p>",
"     Lap banding is done through small incisions, with a laparoscope. The band can be adjusted after surgery, allowing you to eat more or less food. Adjustments to the size and tightness of the band are made by using a needle to add or remove fluid from a port (a small container under the skin that is connected to the band). Adding fluid to the band makes it tighter which restricts the amount of food you can eat and may help you to lose more weight.",
"    </p>",
"    <p>",
"     Lap banding is a popular choice because it is relatively simple to perform, can be adjusted or removed, and has a low risk of serious complications immediately after surgery. However, weight loss with the lap band depends on your ability to follow the program closely.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       You will need to prepare nutritious meals that \"work with\" the band, not against it. For example, the lap band will not work well if you eat or drink a large amount of liquid calories (like ice cream). The band will not help you to feel full when you",
"       <span class=\"nowrap\">",
"        eat/drink",
"       </span>",
"       liquid calories.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Weight loss ranges from 45 to 75 percent after two years. As an example, a person who is 120 pounds overweight could expect to lose approximately 54 to 90 pounds in the two years after lap banding.",
"    </p>",
"    <p>",
"     The best results with lap band surgery are seen with patients that have frequent follow up. It is important to consider that, although long-term commitment is required with all procedures, you may need to see your surgeon more often after a lap band has been placed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Gastric bypass",
"     </span>",
"     &nbsp;&mdash;&nbsp;Roux-en-Y gastric bypass, also called gastric bypass, helps you to lose weight by reducing the amount of food you can eat and reducing the number of calories and nutrients you absorb from the food you eat.",
"    </p>",
"    <p>",
"     To perform gastric bypass, a surgeon creates a small stomach pouch by dividing the stomach and attaching it to the small intestine (",
"     <a class=\"graphic graphic_figure graphicRef68926 \" href=\"UTD.htm?26/19/26929\">",
"      figure 2",
"     </a>",
"     ). This helps you to lose weight in two ways:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The smaller stomach can hold less food than before surgery. This causes you to feel full after eating a very small amount of food or liquid. Over time, the pouch might stretch, allowing you to eat more food.",
"      </li>",
"      <li>",
"       The body absorbs fewer calories, since food bypasses most of the stomach as well as the upper small intestine. This new arrangement seems to decrease your appetite and change how you break down foods by changing the release of various hormones.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Gastric bypass can be performed as open surgery (through an incision on the abdomen) or laparoscopically, which uses smaller incisions and smaller instruments. Both the laparoscopic and open techniques have risks and benefits. You and your surgeon should work together to decide which surgery, if any, is right for you.",
"    </p>",
"    <p>",
"     Gastric bypass has a high success rate, and people lose an average of 62 to 68 percent of their excess body weight in the first year. Weight loss typically levels off after one to two years, with an overall excess weight loss between 50 and 75 percent. For a person who is 120 pounds overweight, an average of 60 to 90 pounds of weight loss would be expected.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Gastric sleeve",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gastric sleeve, also known as sleeve gastrectomy, is a surgery that reduces the size of the stomach and makes it into a narrow tube (",
"     <a class=\"graphic graphic_figure graphicRef68282 \" href=\"UTD.htm?32/55/33648\">",
"      figure 3",
"     </a>",
"     ). The new stomach is much smaller and produces less of the hormone (ghrelin) that causes hunger, helping you feel satisfied with less food.",
"    </p>",
"    <p>",
"     Sleeve gastrectomy is considered less invasive than gastric bypass because the intestines are not rearranged, and there is less chance of malnutrition. It also appears to control long-term hunger better than lap banding. It might be safer long term than the lap banding because no permanent device is implanted.",
"    </p>",
"    <p>",
"     The gastric sleeve has a good success rate, and people lose an average of 33 percent of their excess body weight in the first year. For a person who is 120 pounds overweight, this would mean losing about 40 pounds in the first year. Like the lap band and gastric bypass, it is important to follow an appropriate diet after surgery.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      WEIGHT LOSS SURGERY COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     A variety of complications can occur with weight loss surgery. The risks of surgery depend upon which surgery you have and any medical problems you had before surgery. Some of the more common early surgical complications (one to six weeks after surgery) include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Bleeding",
"      </li>",
"      <li>",
"       Infection",
"      </li>",
"      <li>",
"       Blockage or tear in the bowels",
"      </li>",
"      <li>",
"       Need for further surgery",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Important medical complications after surgery can include blood clots in the legs or lungs, heart attack, pneumonia, and urinary tract infection. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link\">",
"      \"Complications of bariatric surgery\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link\">",
"      \"Medical management of patients after bariatric surgery\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Complications may happen in any setting, and, if they do, they may be best managed at centers experienced in weight loss surgery. In general, centers with experience in weight loss surgery have:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Board-certified doctors and surgeons",
"      </li>",
"      <li>",
"       A team of support staff (dietitians, counselors, nurses)",
"      </li>",
"      <li>",
"       Long-term follow-up after surgery",
"      </li>",
"      <li>",
"       Hospital staff experienced with the care of weight loss patients. This includes nurses who are trained in the care of patients immediately after surgery and anesthesiologists who are experienced in caring for the morbidly obese.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      EFFECTIVENESS OF WEIGHT LOSS SURGERY",
"     </span>",
"    </p>",
"    <p>",
"     The goal of weight loss surgery is to reduce the risk of illness or death associated with obesity. Weight loss surgery can also help you to feel and look better, reduce the amount of money you spend on medicines, and cut down on sick days. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link\">",
"      \"Medical management of patients after bariatric surgery\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     As an example, weight loss surgery can improve health problems related to obesity (diabetes, high blood pressure, high cholesterol, sleep apnea) to the point that you need less or no medicine.",
"    </p>",
"    <p>",
"     Finally, weight loss surgery might reduce your risk of developing heart disease, cancer, and certain infections.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      AFTER WEIGHT LOSS SURGERY",
"     </span>",
"    </p>",
"    <p>",
"     You will need to stay in the hospital until your team feels that it is safe for you to leave (on average, one to three days). Do not drive if you are taking prescription pain medicine. Begin exercising as soon as possible once you have healed; most weight loss centers will design an exercise program for you.",
"    </p>",
"    <p>",
"     Once you are home, it is important to eat and drink exactly what your doctor and dietitian recommend. You will see your doctor, nurse, and dietitian on a regular basis after surgery to monitor your health, diet, and weight loss. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link\">",
"      \"Medical management of patients after bariatric surgery\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     You will be able to slowly increase how much you eat over time, although it will always be important to:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Eat small, frequent meals and not skip meals",
"      </li>",
"      <li>",
"       Chew your food slowly and completely",
"      </li>",
"      <li>",
"       Avoid eating while \"distracted\" (such as eating while watching TV)",
"      </li>",
"      <li>",
"       Stop eating when you feel full",
"      </li>",
"      <li>",
"       Drink liquids at least 30 minutes before or after eating",
"      </li>",
"      <li>",
"       Avoid foods high in fat or sugar",
"      </li>",
"      <li>",
"       Take vitamin supplements, as recommended",
"      </li>",
"      <li>",
"       Continuously re-assess intake and ensure that you are maintaining healthy habits",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     It can take several months to learn to listen to your body so that you know when you are hungry and when you are full. You may dislike foods you previously loved, and you may begin to prefer new foods. This can be a frustrating process for some people, so talk to your dietitian if you are having trouble.",
"    </p>",
"    <p>",
"     It usually takes between one and two years to lose weight after surgery. After reaching their goal weight, some people have plastic surgery (called \"body contouring\") to remove excess skin from the body, particularly in the abdominal area.",
"    </p>",
"    <p>",
"     Before you decide to have weight loss surgery, you must commit to staying healthy for life. This includes following up with your healthcare team, exercising most days of the week, and eating a sensible diet every day. It can be difficult to develop new eating and exercise habits after weight loss surgery, and you will have to work hard to stick to your goals.",
"    </p>",
"    <p>",
"     Recovering from surgery and losing weight can be stressful and emotional, and it is important to have the support of family and friends. Working with a social worker, therapist, or support group can help you through the ups and downs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804364979\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11569180\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/31/14835?source=see_link\">",
"      Patient information: Weight loss surgery (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=see_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/30/23010?source=see_link\">",
"      Patient information: My child is overweight (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/53/3923?source=see_link\">",
"      Patient information: Health risks of obesity (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/55/3954?source=see_link\">",
"      Patient information: Care after weight loss surgery (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11569234\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"      Patient information: Sleep apnea in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2617?source=see_link\">",
"      Approach to the patient with weight loss",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link\">",
"      Behavioral strategies in the treatment of obesity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link\">",
"      Dietary therapy for obesity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link\">",
"      Drug therapy of obesity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=see_link\">",
"      Role of physical activity and exercise in obese adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"      Surgical management of severe obesity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link\">",
"      Complications of bariatric surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link\">",
"      Medical management of patients after bariatric surgery",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/weightlosssurgery.html\">",
"      www.nlm.nih.gov/medlineplus/weightlosssurgery.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://win.niddk.nih.gov/publications/gastric.htm\">",
"      file://win.niddk.nih.gov/publications/gastric.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     UpToDate wishes to acknowledge Kelly Crowley for her contributions to this topic.",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?9/37/9811/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?9/37/9811?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9811/abstract/1\">",
"      Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9811/abstract/2\">",
"      Ballantyne GH. Measuring outcomes following bariatric surgery: weight loss parameters, improvement in co-morbid conditions, change in quality of life and patient satisfaction. Obes Surg 2003; 13:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9811/abstract/3\">",
"      Balsiger BM, Murr MM, Poggio JL, Sarr MG. Bariatric surgery. Surgery for weight control in patients with morbid obesity. Med Clin North Am 2000; 84:477.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f9_37_9811=[""].join("\n");
var outline_f9_37_9811=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           WEIGHT LOSS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SHOULD I HAVE SURGERY TO LOSE WEIGHT?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PREPARING FOR WEIGHT LOSS SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           TYPES OF WEIGHT LOSS SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           WEIGHT LOSS SURGERY COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           EFFECTIVENESS OF WEIGHT LOSS SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           AFTER WEIGHT LOSS SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/2/39\" title=\"figure 1\">",
"           Lap band PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/19/26929\" title=\"figure 2\">",
"           Roux en Y gastric bypass PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/55/33648\" title=\"figure 3\">",
"           Sleeve gastrectomy PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?5/27/5565\" title=\"table 1\">",
"           Comparison of weight loss surgeries",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        CALCULATORS",
"       </h1>",
"       <div id=\"relatedCalculators\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"UTD.htm?41/23/42366?source=related_link\" title=\"calculator 1\">",
"           Calculator: Body mass index for adults (Patient information)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"UTD.htm?36/47/37630?source=related_link\" title=\"calculator 2\">",
"           Calculator: Body mass index for adults (Metric, Patient information)",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f9_37_9812="Magaldrate and simethicone: Patient drug information";
var content_f9_37_9812=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Magaldrate and simethicone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/39/44660?source=see_link\">",
"     see \"Magaldrate and simethicone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691593",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease too much gas in the stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691873",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn and upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702428",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to magaldrate, simethicone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Appendicitis, colostomy, diverticulitis, ileostomy, or ulcerative colitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take other drugs within 1 hour of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12068 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_37_9812=[""].join("\n");
var outline_f9_37_9812=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019985\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019987\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019986\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019991\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019992\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019994\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019989\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019990\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019995\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019996\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/39/44660?source=related_link\">",
"      Magaldrate and simethicone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_37_9813="Insulin lispro protamine and insulin lispro: Patient drug information";
var content_f9_37_9813=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Insulin lispro protamine and insulin lispro: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12551?source=see_link\">",
"     see \"Insulin lispro protamine and insulin lispro: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/19/3382?source=see_link\">",
"     see \"Insulin lispro protamine and insulin lispro: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2176667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HumaLOG&reg; Mix 50/50&trade;;",
"     </li>",
"     <li>",
"      HumaLOG&reg; Mix 50/50&trade; KwikPen&trade;;",
"     </li>",
"     <li>",
"      HumaLOG&reg; Mix 75/25&trade;;",
"     </li>",
"     <li>",
"      HumaLOG&reg; Mix 75/25&trade; KwikPen&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2186198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humalog&reg; Mix 25",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702304",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to insulin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 80 or older, use this drug with care. You could be more sensitive to low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696704",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep workouts the same. More workouts may lower your insulin needs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699163",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use out dated insulin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2807179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not mix this insulin in the same syringe with other types of insulin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695819",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 15 minutes before or right after a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3629482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Give a missed shot as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3629483",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next shot, skip the missed shot and go back to your normal time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699566",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened containers in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699214",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may store opened vials at room temperature or in a refrigerator. If stored at room temperature, throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699518",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store opened pens at room temperature. Throw away any part not used after 10 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699284",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect opened containers from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699285",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect opened containers from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11549 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-BD889E7001-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_37_9813=[""].join("\n");
var outline_f9_37_9813=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2176667\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2186198\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018634\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018633\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018638\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018639\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018641\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018636\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018637\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018642\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018643\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12551?source=related_link\">",
"      Insulin lispro protamine and insulin lispro: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/19/3382?source=related_link\">",
"      Insulin lispro protamine and insulin lispro: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_37_9814="Transjugular liver biopsy";
var content_f9_37_9814=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transjugular liver biopsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/37/9814/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/37/9814/contributors\">",
"     Jonathan B Kruskal, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/37/9814/contributors\">",
"     Felipe B Collares, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/37/9814/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/37/9814/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/37/9814/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/37/9814/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/37/9814/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the progress and advances in clinical medicine, biochemical analysis, and diagnostic imaging, histologic examination of hepatic tissue still has an important role in the management of patients with liver diseases. Percutaneous liver biopsy has proven to be fast, safe, and efficient, to the point of becoming the gold standard for liver tissue sampling.",
"   </p>",
"   <p>",
"    However, percutaneous liver biopsy involves transection of the liver capsule, and patients taking anticoagulants or with coagulopathies are at an increased risk for intraperitoneal hemorrhage (",
"    <a class=\"graphic graphic_table graphicRef78374 \" href=\"UTD.htm?27/15/27899\">",
"     table 1",
"    </a>",
"    ). Other factors such as morbid obesity and high-volume ascites also represent a challenge for the percutaneous approach, increasing the risks associated with the procedure. Consequently, alternative techniques such as transjugular liver biopsy were developed to permit harvesting of liver tissue in patients with contraindications to the percutaneous procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9814/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=see_link\">",
"     \"Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review transjugular liver biopsy. Percutaneous liver biopsy, transjugular intrahepatic portosystemic shunting, and the interpretation of biopsy specimens are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=see_link\">",
"     \"Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34359?source=see_link\">",
"     \"Indications for the use of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30506?source=see_link\">",
"     \"Interpretation of liver biopsy specimens\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363272644\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver biopsy provides useful information that can be used for the diagnosis, prognosis, staging, and management of patients with acute or chronic liver diseases (",
"    <a class=\"graphic graphic_table graphicRef77571 \" href=\"UTD.htm?27/42/28331\">",
"     table 2",
"    </a>",
"    ). Indications for biopsy include characterization of parenchymal liver diseases, evaluation of abnormal liver function studies, characterization of abnormalities seen on imaging studies, detection and staging of adverse effects of drug treatment, evaluation of liver status following transplantation, evaluation of acute liver failure, and evaluation of fever of unknown origin.",
"   </p>",
"   <p>",
"    Unlike a percutaneous biopsy, the transjugular approach accesses the liver parenchyma through the superior vena cava and hepatic vein and obtains hepatic tissue without traversing the liver capsule. Possible bleeding from the biopsy site is directed into the access vein, minimizing the risk of intraperitoneal hemorrhage.",
"   </p>",
"   <p>",
"    Transjugular liver biopsy is safe and well tolerated and is generally the first-line option for patients in whom the percutaneous approach is suboptimal, contraindicated, or has previously failed (",
"    <a class=\"graphic graphic_table graphicRef78374 \" href=\"UTD.htm?27/15/27899\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83413 \" href=\"UTD.htm?2/63/3067\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9814/abstract/1,3-9\">",
"     1,3-9",
"    </a>",
"    ]. In addition, transjugular access directly into the hepatic vein allows the hepatic venous pressure gradient to be measured (HVPG). The HVPG can be used to predict a patient's risk of developing varices or variceal bleeding and to guide the management of patients with portal hypertension due to cirrhosis. Finally, a transjugular approach can also be used in patients with a simultaneous indication for transjugular intrahepatic portosystemic shunt (TIPS) placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link&amp;anchor=H157005766#H157005766\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\", section on 'Hepatic venous pressure gradient'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The conventional transjugular liver biopsy technique results in a non-targeted biopsy and is usually reserved for diffuse liver diseases. The transjugular approach should not be used if a targeted tissue sample is required. Instead, such patients require a targeted biopsy using a technique such as ultrasound-guided percutaneous biopsy, or a biopsy obtained during laparoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=see_link&amp;anchor=H17#H17\">",
"     \"Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy\", section on 'Role of radiologic guidance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=see_link&amp;anchor=H59203445#H59203445\">",
"     \"Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy\", section on 'Laparoscopic liver biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the technique requires administration of intravenous contrast material, relative contraindications to transjugular liver biopsy include the presence of renal failure and a history of prior adverse reaction to iodinated contrast material. The technique may not be feasible in patients with stenosis or occlusion of the right jugular vein, vena cava, or hepatic veins, such as those with Budd Chiari syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the biopsy, a complete physical examination and review of the clinical history, laboratory results, imaging findings, current medications, and allergy history should be performed. Written informed consent should be obtained, explaining the procedure and the risks and benefits that may be expected. Wherever possible, pre-existing coagulopathies should be corrected, and anticoagulants should be discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43094?source=see_link\">",
"     \"Informed consent\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The procedure is performed under local anesthesia with moderate procedural sedation. There is no consensus regarding the need for antibiotic prophylaxis for transjugular liver biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9814/abstract/10\">",
"     10",
"    </a>",
"    ]. The Society for Interventional Radiology notes that antibiotic prophylaxis for transjugular intrahepatic portosystemic shunt placement with an antibiotic such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    is appropriate, but it does not comment on the use of antibiotics in patients undergoing transjugular liver biopsy. In the absence of clear guidelines, antibiotic prophylaxis may be administered at the discretion of the interventionalist. Our approach is to provide antibiotic prophylaxis with an antibiotic such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    or ceftriaxone when performing transjugular liver biopsies. The patient's hemodynamic parameters should be monitored throughout the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients are placed in a supine position on the angiography table with their neck exposed and their head turned away from the side of venous access. The right internal jugular vein (IJ) puncture is preferred because it offers more direct access to the superior vena cava (SVC), inferior vena cava (IVC), and the hepatic veins, facilitating the selective catheterization of the latter [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9814/abstract/11\">",
"     11",
"    </a>",
"    ]. The right neck is prepared and draped in standard sterile fashion, and after administration of local anesthesia, intravenous access is obtained under ultrasonographic guidance with a micropuncture needle set using the Seldinger technique. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link\">",
"     \"Overview of central venous access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The guidewire is advanced into the IVC under fluoroscopic guidance, followed by a transjugular vascular sheath. Selective catheterization of the right hepatic vein is performed through the vascular sheath with a combination of a hydrophilic guidewire and a 5 French multipurpose curved catheter. The right hepatic vein is usually selected because of its favorable orientation, but the biopsy can also be safely performed through the middle hepatic vein. The catheter is then advanced over the wire into the right hepatic vein, and a venogram is obtained to depict the venous anatomy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83415 \" href=\"UTD.htm?18/20/18756\">",
"     image 1",
"    </a>",
"    ). The hepatic venous pressure gradient can be measured at this point if indicated. The venous pressure is recorded with the catheter in both wedged and free hepatic vein positions to estimate the pressure gradient between the portal and systemic circulations, respectively. Alternatively, the estimated portal venous pressure can be measured using an occlusion balloon catheter.",
"   </p>",
"   <p>",
"    A stiff guidewire is then inserted through the catheter into the right hepatic vein, over which the vascular sheath can be directed into the hepatic circulation. Next, a 7 French catheter with a curved metallic cannula is advanced through the vascular sheath and over the guidewire into the right hepatic vein under fluoroscopic guidance (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83416 \" href=\"UTD.htm?15/15/15604\">",
"     image 2",
"    </a>",
"    ). Confirmation of adequate positioning into the hepatic vein approximately 4 cm distal to the IVC can be performed by injecting a small amount of iodinated contrast material. Keeping the sheath and catheter in place, the biopsy needle is inserted coaxially into the access assembly and advanced to the tip of the catheter. The catheter with the metallic cannula is then rotated in the desired direction, away from the center of vessel lumen, toward the liver parenchyma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83417 \" href=\"UTD.htm?39/36/40515\">",
"     image 3",
"    </a>",
"    ). The biopsy device is advanced out of the tip of the catheter, through the wall of the hepatic vein, and into the liver parenchyma. Once the biopsy device is within the liver parenchyma, a tissue sample is harvested with the semi-automated spring-fire mechanism (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83418 \" href=\"UTD.htm?37/39/38515\">",
"     image 4",
"    </a>",
"    ). Usually three adequate samples (at least 15 mm in length) are obtained.",
"   </p>",
"   <p>",
"    The biopsy may be performed under fluoroscopic guidance to avoid a deep puncture that could potentially perforate the liver capsule and cause bleeding complications. Our practice is to perform transjugular liver biopsies under real-time fluoroscopic guidance in order to increase safety and provide better control during needle advancement. This is particularly important in patients with small, cirrhotic livers, as there is a reduced distance between the hepatic vein and the liver capsule in such patients.",
"   </p>",
"   <p>",
"    After the biopsy, a hepatic venogram is often performed to exclude active extravasation. In the unlikely event of a venous bleed, embolization of the site with a gelatin sponge can be performed. Arterial bleeding after the biopsy is a more serious complication that is usually detected when the patient develops hemodynamic instability and a hematocrit drop following the procedure. Arterial bleeding often requires hepatic arteriogram with embolization of the bleeding site. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=see_link&amp;anchor=H4#H4\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\", section on 'Embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After the venogram (if done), the catheter, metallic cannula, and vascular sheath are then removed. Manual compression at the puncture site on the right neck is performed to achieve hemostasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363273077\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obtaining adequate tissue is essential for accurate histological interpretation. According to current recommendations, the specimens should be at least 15 mm long and contain at least six complete portal tracts to be considered optimal for diagnosis of diffuse liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9814/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnostic and prognostic value of liver biopsies is significantly improved when multiple liver specimens (at least three individual non-fragmented samples) are submitted for analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9814/abstract/2,12,13\">",
"     2,12,13",
"    </a>",
"    ]. In general, transjugular liver biopsies are diagnostic in 85 to 100 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9814/abstract/2,5,14,15\">",
"     2,5,14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30506?source=see_link&amp;anchor=H180144294#H180144294\">",
"     \"Interpretation of liver biopsy specimens\", section on 'Principles of evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications from transjugular liver biopsy may be minor or severe (",
"    <a class=\"graphic graphic_table graphicRef83414 \" href=\"UTD.htm?16/2/16427\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9814/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. The reported overall complication rate from transjugular liver biopsy ranges from 1 to 20 percent, with an overall mortality of 0.1 to 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9814/abstract/1,23,24\">",
"     1,23,24",
"    </a>",
"    ]. Complications were observed in 2.5 percent of transjugular liver biopsies in a retrospective analysis of 601 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9814/abstract/5\">",
"     5",
"    </a>",
"    ]. Minor complications such as abdominal pain and fever are usually managed conservatively, whereas major complications often require intervention.",
"   </p>",
"   <p>",
"    Major complications include hemoperitoneum, hemobilia, and fistulas between hepatic vein, hepatic artery, portal vein, and biliary system. Capsular puncture and consequent intraperitoneal hemorrhage is a major concern in this population, with increased risk in patients with small cirrhotic livers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9814/abstract/1\">",
"     1",
"    </a>",
"    ]. Significant hemobilia and hemoperitoneum are managed by aggressive transfusion of red blood cells and fresh-frozen plasma. In patients who continue to have bleeding, diagnostic hepatic angiography and venography followed by coil embolization are indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9814/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=see_link\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/39/4721?source=see_link\">",
"       \"Patient information: Liver biopsy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11834133\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transjugular liver biopsy is a safe and efficient alternative to obtain adequate liver tissue specimens for patients with diffuse liver disease when a percutaneous procedure is either suboptimal or contraindicated (",
"      <a class=\"graphic graphic_table graphicRef78374 \" href=\"UTD.htm?27/15/27899\">",
"       table 1",
"      </a>",
"      ). Common indications include severe coagulopathy and massive ascites (",
"      <a class=\"graphic graphic_table graphicRef77571 \" href=\"UTD.htm?27/42/28331\">",
"       table 2",
"      </a>",
"      ). In addition, hepatic venous pressure gradient readings can be obtained or a transjugular intrahepatic portosystemic shunt inserted during the procedure. (See",
"      <a class=\"local\" href=\"#H363272644\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Using the transjugular technique permits access to the liver parenchyma through the hepatic vein, avoiding hepatic capsule",
"      <span class=\"nowrap\">",
"       puncture/perforation.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overall complication rate of transjugular liver biopsy ranges from 1 to 20 percent. Major complications include hemoperitoneum, hemobilia, and fistulas between hepatic vein, hepatic artery, portal vein, and biliary system (",
"      <a class=\"graphic graphic_table graphicRef83414 \" href=\"UTD.htm?16/2/16427\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363273131\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and UpToDate would like to thank Drs. Arturo Bravo and Sunil Sheth, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/1\">",
"      Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/2\">",
"      Behrens G, Ferral H, Giusto D, et al. Transjugular liver biopsy: comparison of sample adequacy with the use of two automated needle systems. J Vasc Interv Radiol 2011; 22:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/3\">",
"      Kalambokis G, Manousou P, Vibhakorn S, et al. Transjugular liver biopsy--indications, adequacy, quality of specimens, and complications--a systematic review. J Hepatol 2007; 47:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/4\">",
"      Sheela H, Seela S, Caldwell C, et al. Liver biopsy: evolving role in the new millennium. J Clin Gastroenterol 2005; 39:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/5\">",
"      Mammen T, Keshava SN, Eapen CE, et al. Transjugular liver biopsy: a retrospective analysis of 601 cases. J Vasc Interv Radiol 2008; 19:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/6\">",
"      Miraglia R, Luca A, Gruttadauria S, et al. Contribution of transjugular liver biopsy in patients with the clinical presentation of acute liver failure. Cardiovasc Intervent Radiol 2006; 29:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/7\">",
"      Ahmad A, Hasan F, Abdeen S, et al. Transjugular liver biopsy in patients with end-stage renal disease. J Vasc Interv Radiol 2004; 15:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/8\">",
"      Detrait M, Pothen D, Brenard R, et al. Feasibility, safety and cost-effectiveness of transjugular liver biopsy following major surgery in patients with haemophilia. Haemophilia 2007; 13:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/9\">",
"      Abujudeh H, Huggins R, Patel A. Emergency transjugular liver biopsies in post-liver-transplant patients: technical success and utility. Emerg Radiol 2004; 10:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/10\">",
"      Venkatesan AM, Kundu S, Sacks D, et al. Practice guidelines for adult antibiotic prophylaxis during vascular and interventional radiology procedures. Written by the Standards of Practice Committee for the Society of Interventional Radiology and Endorsed by the Cardiovascular Interventional Radiological Society of Europe and Canadian Interventional Radiology Association [corrected]. J Vasc Interv Radiol 2010; 21:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/11\">",
"      Yavuz K, Geyik S, Barton RE, et al. Transjugular liver biopsy via the left internal jugular vein. J Vasc Interv Radiol 2007; 18:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/12\">",
"      Standish RA, Cholongitas E, Dhillon A, et al. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006; 55:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/13\">",
"      Cholongitas E, Quaglia A, Samonakis D, et al. Transjugular liver biopsy in patients with diffuse liver disease: comparison of three cores with one or two cores for accurate histological interpretation. Liver Int 2007; 27:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/14\">",
"      Azoulay D, Raccuia JS, Roche B, et al. The value of early transjugular liver biopsy after liver transplantation. Transplantation 1996; 61:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/15\">",
"      Velt PM, Choy OG, Shimkin PM, Link RJ. Transjugular liver biopsy in high-risk patients with hepatic disease. Radiology 1984; 153:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/16\">",
"      Kruse-Jarres R, Leissinger CA. Haemobilia after transjugular liver biopsy in a patient with severe haemophilia. Haemophilia 2005; 11:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/17\">",
"      Galan K, Kaplan M, Jakate S. Diagnostic challenges from inadvertent retrieval of adrenal gland tissue with transjugular liver biopsy. J Gastroenterol 2005; 40:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/18\">",
"      Morales CP, Saboorian MH, Miller GL, Lee WM. Adrenal gland sampling during transjugular liver biopsy leads to misdiagnosis of hepatocellular carcinoma. Am J Gastroenterol 1999; 94:3071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/19\">",
"      Bergmann OM, Sun S, Weydert J, Silverman WB. Intrahepatic trifistula causing bilhemia and hemobilia resulting from transjugular liver biopsy in the setting of biliary tract obstruction (with video). Gastrointest Endosc 2007; 66:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/20\">",
"      Dillon BJ, Alomari AI. Delayed formation and rupture of a pseudoaneurysm after transjugular liver biopsy in a pediatric bone marrow transplant patient: imaging and endovascular treatment. Cardiovasc Intervent Radiol 2009; 32:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/21\">",
"      Rogart JN, Aslanian HR. Massive hemobilia after transjugular liver biopsy treated endoscopically and angiographically. Clin Gastroenterol Hepatol 2008; 6:A30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/22\">",
"      Koshy CG, Eapen CE, Lakshminarayan R. Transvenous embolization to treat uncontrolled hemobilia and peritoneal bleeding after transjugular liver biopsy. Cardiovasc Intervent Radiol 2010; 33:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/23\">",
"      McAfee JH, Keeffe EB, Lee RG, R&ouml;sch J. Transjugular liver biopsy. Hepatology 1992; 15:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9814/abstract/24\">",
"      Lebrec D, Goldfarb G, Degott C, et al. Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology 1982; 83:338.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3586 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-220.255.2.156-1001A7F1F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_37_9814=[""].join("\n");
var outline_f9_37_9814=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11834133\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H363272644\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H363273077\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11834133\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H363273131\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3586\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3586|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/20/18756\" title=\"diagnostic image 1\">",
"      Hepatic venogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/15/15604\" title=\"diagnostic image 2\">",
"      Hepatic vein cannulation mid vein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/36/40515\" title=\"diagnostic image 3\">",
"      Hepatic vein cannulation rotated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/39/38515\" title=\"diagnostic image 4\">",
"      Needle advancement into liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3586|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/15/27899\" title=\"table 1\">",
"      Contraindications perc liver bx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/42/28331\" title=\"table 2\">",
"      Indications for liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/63/3067\" title=\"table 3\">",
"      Transjugular liver biopsy indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/2/16427\" title=\"table 4\">",
"      Transjugular liver biopsy complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=related_link\">",
"      Angiographic control of nonvariceal gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34359?source=related_link\">",
"      Indications for the use of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43094?source=related_link\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30506?source=related_link\">",
"      Interpretation of liver biopsy specimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/39/4721?source=related_link\">",
"      Patient information: Liver biopsy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=related_link\">",
"      Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=related_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_37_9815="Wandering atrial pacer tutorial";
var content_f9_37_9815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1046px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wandering atrial pacemaker",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 104px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A wandering atrial pacemaker is present when there are multiple ectopic foci within the atrial myocardium that serve as dominant pacemakers. There is a changing vector of atrial activation which causes a changing P wave morphology and PR interval duration. The QRS intervals have very variable cycle lengths since the ectopic foci have differences of automaticity and rates of impulse generation. The rhythm is therefore irregularly irregular. QRS morphology is not altered from that seen during sinus rhythm, since activation of the ventricular myocardium occurs normally via the His-Purkinje system.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_37_9815=[""].join("\n");
var outline_f9_37_9815=null;
var title_f9_37_9816="Calcium channel blockers in the management of stable angina pectoris";
var content_f9_37_9816=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Calcium channel blockers in the management of stable angina pectoris",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/37/9816/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/37/9816/contributors\">",
"     Joseph P Kannam, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/37/9816/contributors\">",
"     Julian M Aroesty, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/37/9816/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/37/9816/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/37/9816/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/37/9816/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/37/9816/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/37/9816/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers are a heterogeneous group of compounds used in a variety of cardiovascular disorders such as stable angina pectoris, vasospastic angina, hypertension, hypertrophic cardiomyopathy, and supraventricular arrhythmias.",
"   </p>",
"   <p>",
"    This topic review will present the major issues regarding the use of calcium channel blockers in the patient with stable angina and the evidence that these drugs are effective. Their role, compared with other drugs, in the overall management of angina is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium influx into the myocyte initiates a series of events essential for contractility. Calcium entry into the myocyte first triggers intracellular calcium release; the released calcium then binds the regulatory protein troponin, resulting in a calcium-troponin complex which allows actin and myosin to interact and contract. The sequence of events is the same in vascular smooth muscle cells, except that a calcium-calmodulin complex instead of calcium-troponin permits the interaction between actin and myosin. The net effect is vasodilatation; the ensuing fall in blood pressure decreases cardiac work and may contribute to the efficacy of these drugs in the patient with angina.",
"   </p>",
"   <p>",
"    Calcium channel blockers work by blocking the initial calcium influx into myocytes and vascular smooth muscle cells, preventing the cascade of events detailed above. The available calcium channel blocking agents block receptors on the L-type calcium channel which gives rise to a slowly inactivating high threshold current in cardiac cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR AND ADVERSE SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The currently available calcium channel blockers may be categorized into four groups based upon different chemical structures:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The dihydropyridines (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"       nicardipine",
"      </a>",
"      , nitrendipine, and others).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      , which is structurally similar to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=see_link\">",
"       papaverine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       Diltiazem",
"      </a>",
"      , a benzothiazepine derivative.",
"     </li>",
"     <li>",
"      Bepridil, a nonspecific calcium blocker that is infrequently used in the United States.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These classes have varying mechanisms of action, leading to different effects on cardiovascular function and different types of side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dihydropyridines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dihydropyridines have the following actions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They block slow calcium channels in a dose-dependent fashion [",
"      <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      They have a greater selectivity for vascular smooth muscle than for the myocardium, making them more potent vasodilators than either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      They vasodilate coronary arteries, reduce coronary resistance, increase coronary blood flow, and may enhance the development of coronary collaterals [",
"      <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. The vasodilatation and increase in coronary artery blood flow result from the blockade of calcium influx as well as an increase the levels of nitric oxide and bradykinin; therefore, the increase in coronary artery blood flow is a result of",
"      <span class=\"nowrap\">",
"       bradykinin/nitric",
"      </span>",
"      oxide-dependent and -independent mechanisms [",
"      <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      They elicit a strong reflex beta-adrenergic response, making any potential negative inotropic or chronotropic effect clinically insignificant. This adrenergic response often includes a reflex tachycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These actions determine the side effect profile of the dihydropyridines and the clinical settings in which they should or should not be used. Short-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    has a relatively high incidence of adverse side effects, including peripheral edema (not related to heart failure), flushing, headaches, and lightheadedness, all caused by peripheral vasodilatation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=see_link\">",
"     \"Major side effects and safety of calcium channel blockers\"",
"    </a>",
"    .) These symptoms are less common with long-acting nifedipine or second generation dihydropyridines such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    There are several potential problems that must be considered when using a dihydropyridine in a patient with angina.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       Nifedipine",
"      </a>",
"      may exacerbate ischemia in some patients by causing a reflex tachycardia, preventing its use in patients with unstable angina or myocardial infarction (MI).",
"     </li>",
"     <li>",
"      There is only a mild negative inotropic effect, but these agents should be used with caution in patients with severe myocardial depression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Verapamil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    has different physiologic effects from the dihydropyridines because of a different interaction with the calcium channels. Verapamil is effective in angina because it decreases myocardial oxygen demand by acting as a negative inotrope and chronotrope and by lowering the systemic blood pressure. Changes in contractility are minimal in patients without heart disease; however, verapamil can exacerbate heart failure in patients with cardiac dysfunction due to its negative inotropic activity. This effect is more pronounced in patients who are also treated with a beta blocker, a combination that is not generally used. Verapamil also slows cardiac conduction, an effect that may be deleterious in patients with sick sinus syndrome or atrioventricular block.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    is much less potent vasodilator than the dihydropyridines. As a result, side effects such as headache, flushing, peripheral edema, and lightheadedness are less common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diltiazem",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     Diltiazem",
"    </a>",
"    has actions that fall between the dihydropyridines and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       Diltiazem",
"      </a>",
"      is a potent coronary but a mild arterial vasodilator, producing improved blood flow through coronary epicardial vessels, collaterals, and normal and ischemic myocardium, as well as lowering mean arterial pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It may depress sinus node automaticity and AV nodal conduction time but this effect is less prominent than that seen with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       Diltiazem",
"      </a>",
"      is a negative inotrope.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The net effect is that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    may be somewhat better tolerated than the other calcium channel blockers, since it is neither a potent vasodilator nor a myocardial depressant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All calcium channel blockers are effective in the treatment of stable angina pectoris [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/9\">",
"     9",
"    </a>",
"    ]. However, short-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    is limited by reflex tachycardia which may exacerbate ischemia, thereby preventing its use as monotherapy in this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dihydropyridines",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have demonstrated the effectiveness of the dihydropyridines in stable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In the International Multicenter Angina Exercise (IMAGE) trial, 280 patients with chronic stable angina were randomized to six weeks therapy with long-acting preparations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    (20 mg BID) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    (200 mg once daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/10\">",
"     10",
"    </a>",
"    ]. Nifedipine reduced the frequency of angina and increased the mean exercise time to 1-mm ST segment depression. However, the increase in exercise time was less than that seen with controlled-release metoprolol (43 versus 70 seconds, p&lt;0.05).",
"   </p>",
"   <p>",
"    In patients already treated with beta blockers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nitrates, long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    has no significant effect on survival. This was demonstrated in the ACTION trial, in which 7665 patients with angina were randomly assigned to long-acting nifedipine 60 mg daily or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/13\">",
"     13",
"    </a>",
"    ]. At five years, mortality was similar for nifedipine and placebo (1.64 versus 1.53 deaths per 100 patients per year). Nifedipine did significantly reduce the subsequent rates of coronary angiography and bypass surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second generation dihydropyridines (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    ) are also effective antianginal agents. Amlodipine increases exercise duration, decreases the number of anginal attacks, and reduces the consumption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/12\">",
"     12",
"    </a>",
"    ]. It is given once daily (at a dose of five or 10 mg) and is well tolerated. Common side effects of the dihydropyridines are less likely with amlodipine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     Nicardipine",
"    </a>",
"    , a short-acting dihydropyridine with a side effect profile similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , has also been shown to be effective in angina. It is remarkably effective in vasospastic (variant) angina [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reflex tachycardia may limit the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    and, to a lesser degree, the other dihydropyridines in the treatment of stable angina. This can be overcome by the use of nifedipine in combination with a beta blocker. The effectiveness of nifedipine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    versus either drug alone was compared to placebo in a study of 16 patients with exertional angina [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/15\">",
"     15",
"    </a>",
"    ]. Combination therapy decreased the number of ischemic episodes as determined by ST segment depression on 48 hour ambulatory monitoring when compared to monotherapy or placebo (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Combination therapy with beta blockers'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dihydropyridines versus verapamil or diltiazem",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have compared the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    in patients with stable angina. These studies can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report of 32 patients found that exercise time improved from 5.7 minutes with placebo to eight minutes with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      and up to 10 minutes with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/16\">",
"       16",
"      </a>",
"      ]. Side effects included a mild bradycardia with verapamil, a mild tachycardia with nifedipine, and angina in four patients taking nifedipine.",
"     </li>",
"     <li>",
"      Another report of 21 patients in a double blind crossover study showed that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      appeared to be equally effective in improving exercise time, but fewer patients experienced adverse reactions with diltiazem [",
"      <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A large study of 551 patients compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      (10 mg daily) and amlodipine (10 mg daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      (50 mg daily) to extended-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      (480 mg daily given at bedtime) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/19\">",
"       19",
"      </a>",
"      ]. Compared to placebo, all three strategies improved exercise capacity and there was no difference among them in regard to time to symptoms with exercise, time to &ge;1 mm ST segment depression, or number of patients experiencing angina with exercise. However, verapamil and the combination of amlodipine plus atenolol were more effective than amlodipine alone for decreasing myocardial ischemia frequency and duration on ambulatory monitoring, especially in the morning between 6 am and noon.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Verapamil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    has been shown to increase exercise duration, reduce the number of anginal attacks, and decrease the consumption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    tablets in numerous double blind, placebo-controlled randomized trials of patients with chronic stable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/9,20-22\">",
"     9,20-22",
"    </a>",
"    ]. The usual effective dose is 360 to 480",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    is a safe and effective alternative to beta blockers. Verapamil and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    are equally effective in preventing anginal attacks and in prolonging exercise duration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. The choice between the two, therefore, largely depends upon the clinical setting and the side effects of each drug. In recent years, sustained release preparations of verapamil have become available and are as effective as but more convenient than the regular formulation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diltiazem",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     Diltiazem",
"    </a>",
"    has been shown to reduce anginal frequency,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    consumption, and increase exercise performance in patients with chronic stable angina in several randomized placebo controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/9,29-31\">",
"     9,29-31",
"    </a>",
"    ]. The effective antianginal dose is 240 to 360",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Once and twice daily preparations (such as diltiazem CD) have been found to be as effective as the short-acting form [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     Diltiazem",
"    </a>",
"    is as effective as beta blockers in the treatment of chronic stable angina. As an example, one study of 33 patients found no difference in efficacy between diltiazem and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/35\">",
"     35",
"    </a>",
"    ]. Diltiazem is also a safe alternative to beta blockers due to its low incidence of side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Combination therapy with beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with a calcium channel blocker plus a beta blocker is more effective than therapy with either drug alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Verapamil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    plus a beta blocker may be the most effective combination but it is associated with the highest incidence of significant side effects due to the negative and additive inotropic and chronotropic actions of both drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Nifedipine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    and a beta blocker is associated with fewer side effects than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and beta blocker, but is also less efficacious than the combination of beta blockers and other calcium channel blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/37\">",
"     37",
"    </a>",
"    ]. As an example, the IMAGE study described above compared long-acting preparations of nifedipine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    , given alone or in combination [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients received monotherapy for six weeks and combination therapy for another four weeks; exercise testing was performed at both 6 and 10 weeks. The mean increase in exercise time to 1-mm ST segment depression increased with the addition of a second drug (107 versus 37 to 49 seconds with the addition of placebo). However, the anti-ischemic effect from the combination was primarily due to improvement in patients who had not responded to monotherapy rather than to an additive effect of the two drugs. A true additive effect was seen in a minority of patients (14 percent in whom nifedipine was added to metoprolol, and 24 percent in whom metoprolol was added to nifedipine).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Amlodipine",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study randomized 147 patients with angina and a positive exercise test despite optimal beta blockade to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/38\">",
"     38",
"    </a>",
"    ]. After eight weeks of therapy, there was no difference in time to 1 mm ST segment depression, time to chest pain, or exercise duration, but the number of patients with chest pain during exercise testing was lower with amlodipine than placebo. In the subgroup of patients with early onset of angina (&lt;6 minutes) amlodipine significantly increased the time to chest pain and reduced the amount of ST segment depression and the double product at comparable workloads. There was no difference in the frequency of side effects between the two groups.",
"   </p>",
"   <p>",
"    A second study compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    in 97 patients with persistent angina despite",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    therapy and found a significant and equivalent reduction in the frequency of anginal episodes with the two agents [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/39\">",
"     39",
"    </a>",
"    ]. However, patients taking diltiazem reported twice as many adverse reactions than those on amlodipine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Felodipine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    along with or instead of a beta blocker was evaluated in 363 patients with angina despite therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/40\">",
"     40",
"    </a>",
"    ]. The addition of felodipine to metoprolol therapy increased the time to 1 mm ST segment depression and the time to angina during exercise testing and reduced the maximal ST segment depression. In contrast, the exercise test results after replacement of metoprolol with felodipine were not different from those observed during metoprolol therapy.",
"   </p>",
"   <p>",
"    Given these data, the choice of a particular calcium channel blocker-beta blocker combination largely depends upon the clinical setting, the tolerance of side effects, and the severity of ischemic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ARE CALCIUM CHANNEL BLOCKERS SAFE?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding findings as well as other studies suggested an adverse effect on cardiovascular disease in patients treated with short-acting dihydropyridines and high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef51222 \" href=\"UTD.htm?28/33/29213\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. In particular, the marked hemodynamic perturbations of large doses of short-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    when given to such vulnerable patients appeared to increase mortality (",
"    <a class=\"graphic graphic_figure graphicRef76385 \" href=\"UTD.htm?17/14/17645\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These adverse hemodynamic effects are generally not seen when long-acting calcium channel blockers are given to patients with hypertension or stable angina (",
"    <a class=\"graphic graphic_table graphicRef52312 \" href=\"UTD.htm?15/33/15899\">",
"     table 1",
"    </a>",
"    ). The safety of long acting calcium channel blockers, when used for either blood pressure control or relief of angina, was evaluated in a meta-analysis of 15 studies including over 47,000 patients with coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/44\">",
"     44",
"    </a>",
"    ]. There were no significant differences between the calcium channel blockers and other classes of agents (such as angiotensin converting enzyme inhibitors or beta blockers) or placebo in the rates of all-cause mortality, cardiovascular mortality, nonfatal myocardial infarction, or heart failure. A significant 21 percent relative reduction in the risk of stroke and, as expected, a significant reduction in the risk of angina were noted. No apparent difference was seen between dihydropyridine and nondihydropyridine drugs.",
"   </p>",
"   <p>",
"    The FDA has given the long acting and heart rate lowering calcium channel blockers a \"clean bill of health,\" while warning against short acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=see_link&amp;anchor=H9#H9\">",
"     \"Major side effects and safety of calcium channel blockers\", section on 'Serious adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the following suggestions which were made in 2012 guideline on the diagnosis and management of stable ischemic heart disease from the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of",
"    <span class=\"nowrap\">",
"     Physicians/American",
"    </span>",
"    Association for Thoracic",
"    <span class=\"nowrap\">",
"     Surgery/Preventive",
"    </span>",
"    Cardiovascular Nurses",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    for Cardiovascular Angiography and",
"    <span class=\"nowrap\">",
"     Interventions/Society",
"    </span>",
"    of Thoracic Surgeons",
"    <span class=\"nowrap\">",
"     (ACCF/AHA/ACP/AATS/PCNA/SCAI/STS)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9816/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A calcium channel blocker should be prescribed for relief of anginal symptoms if there are contraindications from or adverse reactions to beta blockers.",
"     </li>",
"     <li>",
"      Calcium channel blockers should be added to beta blockers for relief of anginal symptoms if monotherapy with the latter is unsuccessful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following represent the clinically important points in this topic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers or nitrates should be used for the initial treatment of stable angina. A calcium channel blocker should be considered if there are contraindications or adverse reactions to either beta blockers of nitrates or if symptoms are not well controlled with a combination of these agents.",
"     </li>",
"     <li>",
"      All calcium channel blockers are effective in the treatment of stable angina pectoris. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of short-acting dihydropyridines, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      , is limited by reflex tachycardia which may exacerbate ischemia, thereby preventing its use as monotherapy in this disorder. In addition some studies suggest an increase in mortality when these particular calcium channel blockers are used. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cardiovascular and adverse side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combination therapy with a calcium channel blocker plus a beta blocker is more effective than therapy with either drug alone. We suggest choosing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"       felodipine",
"      </a>",
"      before other calcium channel blockers, given their better side effect profiles when used in combination with beta blockers. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Combination therapy with beta blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with stable angina, when a vasoactive component to stable angina is suspected, we suggest a trial of a calcium channel blocker in addition to a beta blocker. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=see_link&amp;anchor=H17#H17\">",
"       \"Variant angina\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Calcium channel blockers, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , should be used with caution in patients with left ventricular systolic dysfunction or heart failure due to their negative inotropic effect. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cardiovascular and adverse side effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/1\">",
"      Kohlhardt M, Fleckenstein A. Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 1977; 298:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/2\">",
"      Bayer R, Rodenkirchen R, Kaufmann R, et al. The effects of nifedipine on contraction and monophasic action potential of isolated cat myocardium. Naunyn Schmiedebergs Arch Pharmacol 1977; 301:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/3\">",
"      Kaltenbach M, Schulz W, Kober G. Effects of nifedipine after intravenous and intracoronary administration. Am J Cardiol 1979; 44:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/4\">",
"      Henry PD, Shuchleib R, Clark RE, Perez JE. Effect of nifedipine on myocardial ischemia: analysis of collateral flow, pulsatile heat and regional muscle shortening. Am J Cardiol 1979; 44:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/5\">",
"      Kitakaze M, Asanuma H, Takashima S, et al. Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs. Circulation 2000; 101:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/6\">",
"      Casolo GC, Balli E, Poggesi L, Gensini GF. Increase in number of myocardial ischemic episodes following nifedipine administration in two patients. Detection of silent episodes by Holter monitoring and role of heart rate. Chest 1989; 95:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/7\">",
"      Joyal M, Cremer KF, Pieper JA, et al. Systemic, left ventricular and coronary hemodynamic effects of intravenous diltiazem in coronary artery disease. Am J Cardiol 1985; 56:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/8\">",
"      Bache RJ, Dymek DJ. Effect of diltiazem on myocardial blood flow. Circulation 1982; 65:I19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/9\">",
"      Krikler DM. Calcium antagonists for chronic stable angina pectoris. Am J Cardiol 1987; 59:95B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/10\">",
"      Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996; 27:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/11\">",
"      Sherman LG, Liang CS. Nifedipine in chronic stable angina: a double-blind placebo-controlled crossover trial. Am J Cardiol 1983; 51:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/12\">",
"      Taylor SH. Usefulness of amlodipine for angina pectoris. Am J Cardiol 1994; 73:28A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/13\">",
"      Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/14\">",
"      Agre K. An overview of the safety and efficacy of nicardipine in clinical trials. Am J Cardiol 1987; 59:31J.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/15\">",
"      Dargie HJ, Lynch PG, Krikler DM, et al. Nifedipine and propranolol: a beneficial drug interaction. Am J Med 1981; 71:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/16\">",
"      Subramanian VB, Bowles MJ, Khurmi NS, et al. Randomized double-blind comparison of verapamil and nifedipine in chronic stable angina. Am J Cardiol 1982; 50:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/17\">",
"      Wallace WA, Wellington KL, Murphy GW, Liang CS. Comparison of antianginal efficacies and exercise hemodynamic effects of nifedipine and diltiazem in stable angina pectoris. Am J Cardiol 1989; 63:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/18\">",
"      Klinke WP, Kvill L, Dempsey EE, Grace M. A randomized double-blind comparison of diltiazem and nifedipine in stable angina. J Am Coll Cardiol 1988; 12:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/19\">",
"      Frishman WH, Glasser S, Stone P, et al. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 1999; 83:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/20\">",
"      Weiner DA, Klein MD. Verapamil therapy for stable exertional angina pectoris. Am J Cardiol 1982; 50:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/21\">",
"      Subramanian VB, Lahiri A, Paramasivan R, Raftery EB. Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise. Lancet 1980; 1:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/22\">",
"      Brodsky SJ, Cutler SS, Weiner DA, et al. Treatment of stable angina of effort with verapamil: a double-blind, placebo-controlled randomized crossover study. Circulation 1982; 66:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/23\">",
"      Pine MB, Citron PD, Bailly DJ, et al. Verapamil versus placebo in relieving stable angina pectoris. Circulation 1982; 65:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/24\">",
"      Frishman WH, Klein NA, Klein P, et al. Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris. A placebo-controlled double-blind randomized crossover trial. Am J Cardiol 1982; 50:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/25\">",
"      Subramanian VB, Bowles MJ, Davies AB, Raftery EB. Calcium channel blockade as primary therapy for stable angina pectoris. A double-blind placebo-controlled comparison of verapamil and propranolol. Am J Cardiol 1982; 50:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/26\">",
"      Johnson SM, Mauritson DR, Corbett JR, et al. Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. Am J Med 1981; 71:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/27\">",
"      Weiner DA, Klein MD, Cutler SS. Efficacy of sustained-release verapamil in chronic stable angina pectoris. Am J Cardiol 1987; 59:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/28\">",
"      Cutler NR, Anders RJ, Jhee SS, et al. Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. Am J Cardiol 1995; 75:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/29\">",
"      Hossack KF, Pool PE, Steele P, et al. Efficacy of diltiazem in angina on effort: a multicenter trial. Am J Cardiol 1982; 49:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/30\">",
"      Strauss WE, McIntyre KM, Parisi AF, Shapiro W. Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: report of a cooperative clinical trial. Am J Cardiol 1982; 49:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/31\">",
"      Lindenberg BS, Weiner DA, McCabe CH, et al. Efficacy and safety of incremental doses of diltiazem for the treatment of stable angina pectoris. J Am Coll Cardiol 1983; 2:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/32\">",
"      Weiner DA, Cutler SS, Klein MD. Efficacy and safety of sustained-release diltiazem in stable angina pectoris. Am J Cardiol 1986; 57:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/33\">",
"      Nadeau C, Hilton D, Savard D, et al. Three-month efficacy and safety of once-daily diltiazem in chronic stable angina pectoris. Am J Cardiol 1995; 75:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/34\">",
"      Thadani U, Glasser S, Bittar N, Beach CL. Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. Diltiazem CD Study Group. Am J Cardiol 1994; 74:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/35\">",
"      van Dijk RB, Lie KI, Crijns HJ. Diltiazem in comparison with metoprolol in stable angina pectoris. Eur Heart J 1988; 9:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/36\">",
"      Strauss WE, Parisi AF. Superiority of combined diltiazem and propranolol therapy for angina pectoris. Circulation 1985; 71:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/37\">",
"      Leon MB, Rosing DR, Bonow RO, Epstein SE. Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris. Am J Cardiol 1985; 55:69B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/38\">",
"      Dunselman PH, van Kempen LH, Bouwens LH, et al. Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Am J Cardiol 1998; 81:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/39\">",
"      Knight CJ, Fox KM. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Studies in Angina Research (CESAR) Investigators. Am J Cardiol 1998; 81:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/40\">",
"      Dunselman P, Liem AH, Verdel G, et al. Addition of felodipine to metoprolol vs replacement of metoprolol by felodipine in patients with angina pectoris despite adequate beta-blockade. Results of the Felodipine ER and Metoprolol CR in Angina (FEMINA) Study. Working Group on Cardiovascular Research, The Netherlands (WCN). Eur Heart J 1997; 18:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/41\">",
"      Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/42\">",
"      Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/43\">",
"      Kloner RA. Nifedipine in ischemic heart disease. Circulation 1995; 92:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/44\">",
"      Bangalore S, Parkar S, Messerli FH. Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. Am J Med 2009; 122:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/45\">",
"      Marwick C. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA 1996; 275:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/46\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:e354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9816/abstract/47\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:3097.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1471 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_37_9816=[""].join("\n");
var outline_f9_37_9816=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CARDIOVASCULAR AND ADVERSE SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dihydropyridines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Verapamil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diltiazem",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dihydropyridines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dihydropyridines versus verapamil or diltiazem",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Verapamil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diltiazem",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Combination therapy with beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Verapamil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Nifedipine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Amlodipine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Felodipine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ARE CALCIUM CHANNEL BLOCKERS SAFE?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1471\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1471|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/33/29213\" title=\"figure 1\">",
"      Calcium blockers and MI risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/14/17645\" title=\"figure 2\">",
"      Short acting nifedipine in CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1471|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/33/15899\" title=\"table 1\">",
"      Short versus long acting CCBs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=related_link\">",
"      Variant angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_37_9817="Primary ciliary dyskinesia (immotile-cilia syndrome)";
var content_f9_37_9817=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary ciliary dyskinesia (immotile-cilia syndrome)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/37/9817/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/37/9817/contributors\">",
"     Sten-Erik Bergstr&ouml;m, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/37/9817/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/37/9817/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/37/9817/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/37/9817/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/37/9817/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26740018\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary ciliary dyskinesia (PCD, also called the immotile-cilia syndrome) is characterized by congenital impairment of mucociliary clearance (MCC) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Clinical manifestations include chronic cough, chronic rhinitis, and chronic sinusitis. Otitis and otosalpingitis are common in childhood, as are nasal polyposis and agenesis of the frontal sinuses. The underlying cause is a defect of cilia in the airways, making them unable to beat (ciliary immotility), unable to beat normally (ciliary dyskinesia), or to be missing altogether (ciliary aplasia). It is an inherited disease that has been described from most parts of the world and with equal prevalence in men and women of approximately one in 10,000 to 30,000 individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the embryonic, nodal cilia are also defective, body asymmetry is randomized so that approximately 50 percent of the patients have situs inversus totalis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. When situs inversus, chronic sinusitis, and bronchiectasis occur together, an individual is said to have Kartagener's syndrome, a subgroup of primary ciliary dyskinesia that has a prevalence of around one in 20,000 to 40,000 individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/5\">",
"     5",
"    </a>",
"    ]. Bronchiectasis may develop in young persons, but is never present at birth; thus, no individual is born with a fully developed Kartagener's triad.",
"   </p>",
"   <p>",
"    The genetics, clinical manifestations, diagnosis, and management of PCD are reviewed here. The evaluation and treatment of bronchiectasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link\">",
"     \"Treatment of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740025\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary ciliary dyskinesia (PCD) is inherited as an autosomal recessive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/9\">",
"     9",
"    </a>",
"    ]. It is a highly heterogeneous syndrome that can be caused by a defect in any of the many polypeptide species within the axoneme (central core) of cilia or of sperm flagella, in other proteins that are present in the ciliary membrane and matrix, or in proteins needed for the proper assembly of cilia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. Different components may be missing or defective in different patients, and different clinical manifestations may develop depending upon the nature of the lesion. Families may have different mutated genes, but identical clinical symptoms.",
"   </p>",
"   <p>",
"    Extensive locus heterogeneity of PCD is suspected, but in some cases it has been possible to identify a specific chromosomal locus and gene product [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. As an example, on the basis of linkage analysis from 25 separate families, a locus on chromosome 5p was identified that encodes the axonemal dynein heavy chain 5 protein called DNAH5 (MIM 603335) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. From these family studies, four homozygous and six heterozygous mutations of DNAH5 were identified, all in association with clinical PCD and ultrastructurally abnormal outer dynein arms. Complete absence of DNAH5 along the ciliary axoneme results in immobility, while absence of DNAH5 in the distal portion of the axoneme causes impaired mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of other genes are associated with PCD, including the dynein arm genes DNAI1, which encodes the outer dynein arm intermediate chain, and DNAH11, which is associated with normal appearing dynein arms but impaired function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. Radial spoke head gene mutations (eg, RSPH4A, RSPH9) have been identified and appear to be associated with PCD, but not situs inversus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/23\">",
"     23",
"    </a>",
"    ]. Mutations in DNAI1 and DNAH5 are present in approximately 30 to 38 percent of families with PCD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The trait of situs inversus apparently has an element of random determination [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/3,25\">",
"     3,25",
"    </a>",
"    ]. Rather than having one gene for situs solitus (organs in their normal position) and one for situs inversus, the nodal cilia of the embryo are responsible for controlling the normal position of heart and visceral organs, and without such control there is an equal chance of situs inversus and situs solitus. Two pairs of monozygotic twins with primary ciliary dyskinesia have been identified; in each pair there was one twin with situs inversus and one with situs solitus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740032\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is considerable variation in the clinical presentation of primary ciliary dyskinesia, although the most common features are recurrent infections of the upper and lower respiratory tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740039\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns with primary ciliary dyskinesia often suffer from mild respiratory distress [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. An increased incidence of respiratory infections with chronic cough and expectoration of mucopurulent sputum is commonly encountered as the infant grows [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/27,30\">",
"     27,30",
"    </a>",
"    ]. These symptoms tend to increase during the course of the day rather than peak in the morning, as they do in smoker's bronchitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44662?source=see_link\">",
"     \"Clinical manifestations and evaluation of bronchiectasis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with bronchiectasis generally manifest auscultatory crackles and may have wheezes that mimic asthma, particularly in children.",
"   </p>",
"   <p>",
"    Common findings on chest radiograph and CT scan are a moderate degree of hyperinflation, peribronchial thickening, atelectasis, and bronchiectasis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54505 graphicRef70358 \" href=\"UTD.htm?19/2/19492\">",
"     image 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/31\">",
"     31",
"    </a>",
"    ]. Cylindrical or saccular bronchiectasis may occur, even in childhood, and usually affects the middle and lower lobes and the lingula [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/32\">",
"     32",
"    </a>",
"    ]. Bronchiectasis is present on HRCT in all adults and approximately 50 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/33\">",
"     33",
"    </a>",
"    ]. Multiple, diffuse small centrilobular nodules up to 2 mm are sometimes seen, probably representing bronchiolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spirometry often reveals mild to moderate airway obstruction with variable responsiveness to bronchodilators [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/35\">",
"     35",
"    </a>",
"    ]. The major infecting bacteria are Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and less commonly, Pseudomonas aeruginosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740046\">",
"    <span class=\"h2\">",
"     Rhinosinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A constantly runny nose and year-round nasal congestion may be noted beginning in early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/24,27\">",
"     24,27",
"    </a>",
"    ]. Uncomplicated common colds do not seem to occur more often in PCD than in normal subjects, nor do they usually have a more severe course. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26537?source=see_link\">",
"     \"Microbiology and antibiotic management of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nasal polyposis is frequently present and most patients develop chronic sinusitis, involving the maxillary, ethmoidal, and frontal sinuses, although the frontal sinuses often fail to develop [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/36\">",
"     36",
"    </a>",
"    ]. The absence of a frontal sinus often gives the voice a somewhat nasal tone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740053\">",
"    <span class=\"h2\">",
"     Otitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The otologic complications of PCD are a consequence of defective ciliary function in the Eustachian tube and middle ear cleft, leading to poor mucociliary clearance. Chronic secretory otitis media with recurrent episodes of acute otitis media is present during childhood and adolescence, but these problems become much less frequent following puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/24,37\">",
"     24,37",
"    </a>",
"    ]. Conductive hearing loss is common [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=see_link&amp;anchor=H22#H22\">",
"     \"Acute otitis media in adults (suppurative and serous)\", section on 'Otitis media with effusion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link&amp;anchor=H18#H18\">",
"     \"Acute otitis media in children: Treatment\", section on 'Recurrent AOM'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740060\">",
"    <span class=\"h2\">",
"     Situs inversus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Situs inversus, when present in patients with primary ciliary dyskinesia, occurs normally as a complete reversal of the circulatory system and the viscera. This has no serious adverse health consequences per se, and the condition often goes undetected until a chest radiograph is obtained. Situs inversus is a very useful sign when primary ciliary dyskinesia is being considered, but as described above, is present only in approximately 50 percent of patients with primary ciliary dyskinesia. Isolated situs inversus has a prevalence of about one in 10,000 in Scandinavia, and only about 20 to 25 percent of persons with situs inversus have chronic bronchitis and sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740067\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue and headaches are common complaints and may be caused by chronic sinusitis, although the headaches may persist even during infection-free periods. Hydrocephalus has been described from several persons with primary ciliary dyskinesia, and impaired function of ependymal cilia may be at least partially responsible [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740074\">",
"    <span class=\"h2\">",
"     Fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most men with this syndrome have living but immotile spermatozoa and are infertile, although some have motile spermatozoa but immotile cilia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/43\">",
"     43",
"    </a>",
"    ]. Women likewise have decreased fertility, with fewer than 50 percent successfully completing pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/4,44\">",
"     4,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740081\">",
"    <span class=\"h2\">",
"     Associated abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other congenital abnormalities are occasionally associated with primary ciliary dyskinesia, including transposition of the great vessels and other cardiac abnormalities, pyloric stenosis, and epispadias. Cardiac evaluation is suggested for most patients since the incidence of congenital heart disease with heterotaxy is reported to be 200-fold higher in PCD than the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740088\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The crucial diagnostic feature of primary ciliary dyskinesia is an inborn error of the cilia, rendering them immotile, dysmotile, or missing. A number of tests have been employed and each has advantages and disadvantages (",
"    <a class=\"graphic graphic_table graphicRef77133 \" href=\"UTD.htm?4/59/5052\">",
"     table 1",
"    </a>",
"    ). Tests measuring nasal nitric oxide and mucociliary clearance are useful for screening, but require confirmation with tests of ciliary function and ultrastructure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740095\">",
"    <span class=\"h2\">",
"     Nasal nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measuring the amount of exhaled nasal nitric oxide (nNO), which is very low or absent in patients with PCD, is a useful screening test for patients with a clinical suspicion of PCD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/7,48-52\">",
"     7,48-52",
"    </a>",
"    ]. As the method is reported to have a sensitivity of 97 percent and specificity of 90 percent, a high nNO generally excludes PCD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/47,53-55\">",
"     47,53-55",
"    </a>",
"    ]. Confirmatory testing is required, however, because other respiratory conditions, such as cystic fibrosis, may rarely present with low nNO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7416?source=see_link\">",
"     \"Exhaled nitric oxide analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reduced levels of nasal NO in patients with PCD may be related to alterations in nasal nitric oxide synthetase (NOS) activity. Gene expression studies in nasal biopsy samples from patients with PCD found reduced mRNA levels of the inducible isoform NOS2, which localizes to the apical part of nasal epithelial cells, compared with patients with secondary ciliary dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/56\">",
"     56",
"    </a>",
"    ]. NOS2 gene expression in these biopsies correlated with nasal NO levels. Gene expression of the endothelial isoform NOS3, which is associated with the ciliary basal microtubule membrane, was not reduced. In contrast, a separate report confirmed low levels of NO in nasal and exhaled breath condensates of 15 children with PCD, but found the level of breakdown products (including nitrite) was not low, suggesting that overall NOS activity is not diminished [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740102\">",
"    <span class=\"h2\">",
"     Measures of mucociliary clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is logical to examine ciliary motility in vitro or to measure the mucociliary transport rate in the airways, but there are difficulties with both methods. Cilia from the airways may be immobilized by bacterial toxins; immotility is then acquired rather than inborn and is associated with a different prognosis. Furthermore, mucociliary transport involves a two-component system, and the abnormality may reside in the mucus rather than in the cilia. As an example, patients with cystic fibrosis generate very viscous mucus, through which their normal cilia are unable to propel forward. Mucus from patients with asthma also is more viscous than in healthy persons.",
"   </p>",
"   <p>",
"    Mucociliary transport can be measured in situ by administering an inhalation aerosol of colloid albumin tagged with 99Tc [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Radioactivity within the lungs is then measured repeatedly for two hours and again at 24 hours by profile scanning of the thorax while the patient is supine. The amount of coughing must be monitored for two hours, because coughing acts as a substitute for mucociliary clearance and results in elimination of the isotope from the lungs. This test can only be performed in adults and children over the age of five. In a large series of patients with primary ciliary dysfunction and those suspected of the disease, the test had high positive and negative predictive values compared with nasal ciliary function tests. An absence of mucociliary clearance is a sign of ciliary immotility, dysmotility, or aplasia, which may be inborn or acquired.",
"   </p>",
"   <p>",
"    A somewhat simpler and more rapid technique consists of depositing small particles of saccharin (or dye particles) in the inferior concha and measuring the time required for the taste of the marker to be perceived or for the dye to become visible in the throat. This technique appears less reliable than other methods of diagnosis and cannot be used in small children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740109\">",
"    <span class=\"h2\">",
"     Nasal and bronchial brushing/biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal brushing with a bronchoscopy brush is the preferred method to obtain ciliate epithelium as it is less invasive; the inferior turbinate is brushed for two to three seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/47\">",
"     47",
"    </a>",
"    ]. Flexible bronchoscopy with bronchial brushing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy is performed if the nasal sample is not adequate.",
"   </p>",
"   <p>",
"    The respiratory epithelial cells are rapidly transferred to an isotonic saline solution and examined in the living state, using high speed video microscopy in conjunction with beat frequency measurement to determine whether cilia have normal coordination, beat frequency, and beat pattern. The clinical usefulness of these tests has increased, as their accuracy in distinguishing between primary and secondary ciliary dyskinesia has improved [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electron microscopic analysis is performed when the diagnosis is uncertain after high speed video microscopy, but may also be performed to identify type of ciliary abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/47\">",
"     47",
"    </a>",
"    ]. For electron microscopy, the fresh biopsy is immersed in a glutaraldehyde solution and further processed for ultrastructural investigation, which is the definitive test for PCD. Cross-sections of the cilia are examined by electron microscopy, and specific defects or normal ultrastructure can be visualized (",
"    <a class=\"graphic graphic_picture graphicRef75562 graphicRef77377 \" href=\"UTD.htm?10/12/10438\">",
"     picture 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56415 \" href=\"UTD.htm?14/8/14466\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/63\">",
"     63",
"    </a>",
"    ]. The diversity in ciliary ultrastructure among different patients with the same clinical symptoms is due to the fact that the immotile-cilia syndrome is a heterogeneous disease, and the underlying defect may reside in any of a great number of ciliary genes.",
"   </p>",
"   <p>",
"    A commonly observed defect is the absence of so-called dynein arms (dyneins are the high molecular weight motor proteins responsible for ciliary motility); other reported ultrastructural abnormalities include the absence of radial spokes and absent, or additional, microtubule assemblies. A variant form of ciliary transposition, which results in circular ciliary beating and central microtubule agenesis, has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 10 to 20 percent of cases, the living cilia are seen to be immotile but the ciliary ultrastructure appears quite normal; this likely reflects an underlying defect in membrane pumps or in other proteins not visible in electron micrographs. Use of computer-based image processing algorithms can improve visualization of ultrastructural abnormalities detected using electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740116\">",
"    <span class=\"h2\">",
"     Cell culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cell culture is used to allow redifferentiation of ciliated epithelial cells to reduce false positive tests that mistake secondary loss or dysfunction of cilia for PCD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/47,66,67\">",
"     47,66,67",
"    </a>",
"    ]. This technique is also useful to confirm the presence of less common phenotypes, such as ciliary disorientation, ciliary aplasia, central microtubular agenesis, and inner dynein arm defects.",
"   </p>",
"   <p>",
"    Epithelia from the inferior concha of the nose are obtained with a bronchoscopy brush and maintained in tissue culture with antibiotics (to eliminate any epithelial bacteria) for several weeks. The culture medium is then supplemented with pronase (to separate the individual cells from the epithelium). After several days, cilia are shed and new ones emerge. Healthy cilia are then recognized by their ability to rotate the cells in the tissue medium, whereas the cells will not rotate if primary ciliary dyskinesia is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740123\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing for PCD mutations is not generally part of the initial evaluation, but may be performed if specific variants are suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/47\">",
"     47",
"    </a>",
"    ]. Genetic testing for mutations in the genes DNAI1 and DNAH5 is available through specialized laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/19\">",
"     19",
"    </a>",
"    ]. If biallelic mutations are present, the test is diagnostic. If only one allelic mutation is found, further testing may identify a transallelic mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740130\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other diagnostic tests have been proposed but have a less well-defined role. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A gel electrophoretic examination of dyneins in a biopsy from the nasal epithelium or a sample of ejaculate [",
"      <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using a dynein gene probe to map the corresponding messenger RNA in lung or testicular tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Examining whether spermatozoa are motile or immotile, although care must be taken to differentiate dead from living but immotile spermatozoa. It must also be kept in mind that occasional patients have immotile cilia but normally motile spermatozoa [",
"      <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740137\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;We perform spirometry at every visit; although evidence for this is lacking, we believe that it is useful to obtain an objective measure of lung function.",
"   </p>",
"   <p>",
"    Chest radiographs are relatively insensitive measures of bronchiectasis, but are helpful to evaluate changes in respiratory symptoms.",
"   </p>",
"   <p>",
"    High-resolution computed tomography (HRCT) is more sensitive than conventional chest radiographs for detecting early airway and parenchymal lung changes. It is typically performed to evaluate worsening symptoms or abnormalities on chest radiograph that do not respond to initial therapy As early recognition of deterioration (eg, mucus plugging, atelectasis, pneumonia) is important in patients with PCD, HRCT may be helpful in selected cases (eg, unexplained clinical deterioration, decline in spirometric values, or to determine the extent of bronchiectasis) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of HRCT for monitoring progression of lung disease was compared with spirometry in a retrospective study of 20 patients followed for a median interval of 2.3 years (range 1.3 to 3.4 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/70\">",
"     70",
"    </a>",
"    ]. HRCT scans significantly worsened over time, showing an increased extent of bronchiectasis, mucus plugging, peribronchial thickening, parenchymal abnormalities, and mosaic attenuation, while spirometry remained stable. While HRCT appears more sensitive than spirometry, we do not obtain HRCT for routine monitoring due to concerns about radiation exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740144\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Close, ongoing clinical follow-up is essential, and treatment must be individualized depending upon the specific clinical course of a given patient [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/47,71\">",
"     47,71",
"    </a>",
"    ]. Recommendations are based in part on experience treating patients with cystic fibrosis.",
"   </p>",
"   <p>",
"    Daily chest physiotherapy is important in compensating for diminished or absent mucociliary clearance. The effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/13/29908?source=see_link\">",
"     DNase",
"    </a>",
"    and other mucolytic agents, such as hypertonic saline and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    , has not been fully assessed in PCD, but may be tried, particularly in patients with recurrent infections or ongoing respiratory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/47,72,73\">",
"     47,72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liberal use of antibiotics, even during mild bouts of respiratory infection, is also suggested. We perform regular sputum cultures to identify resistant organisms. Intravenous antibiotics may be required for treatment of Pseudomonas aeruginosa infection, or in cases of severe pneumonia from other bacterial etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/27,71\">",
"     27,71",
"    </a>",
"    ]. Early and definitive treatment of respiratory infections may prevent or delay the evolution of bronchiectasis and minimize the progressive loss of lung function that is otherwise noted [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/27\">",
"     27",
"    </a>",
"    ]. Vaccination against influenza and pneumococcus is advisable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smoking probably causes a more rapid deterioration in lung function, and counseling regarding smoking cessation is essential. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical interventions to treat middle ear disease, maxillary sinusitis, and nasal polyposis may be necessary in a subset of patients. The value of tympanostomy is questionable because otitis tends to be chronic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/37\">",
"     37",
"    </a>",
"    ]. Polypectomy and partial turbinectomy, on the other hand, affect a more long-lasting outcome. Conductive hearing loss should be sought, and hearing aids prescribed as required [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical intervention for bronchiectasis is rarely recommended, but can be beneficial when the disease is localized [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Bilateral lung transplantation is the therapy of choice in patients with end-stage respiratory insufficiency, although heart-lung transplantation or a modified surgical procedure is required in patients with situs inversus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/99?source=see_link\">",
"     \"Heart-lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because ciliary immotility (or dysmotility) commonly is associated with abnormal sperm motility, male patients should be informed about possible infertility, and semen analysis should be offered. In vitro fertilization techniques, particularly intracytoplasmic sperm injection, have been effective in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link\">",
"     \"Evaluation of male infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"     \"Treatment of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persons with primary ciliary dyskinesia generally live an active life and have a normal lifespan. The rate of decline of lung function is much slower than with cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/1,2,35\">",
"     1,2,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740151\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of PCD on lung function was evaluated in a three-decade long observational study [",
"    <a class=\"abstract\" href=\"UTD.htm?9/37/9817/abstract/35\">",
"     35",
"    </a>",
"    ]. Seventy-four patients underwent interval pulmonary function testing over a median of 9.5 (range, 1.5 to 30.2) years. The cohort consisted mostly of children and young adults; the smoking history of these patients was not reported. There was a high degree of variation in the course of lung function after diagnosis. During the observation period, approximately 60 percent had a stable forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ), 30 percent had a decrease of more than 10 percent, and 10 percent had a greater than 10 percent improvement. The variation in lung function was not related to age or level of lung function at the time of diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26814682\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"   </p>",
"   <p>",
"    Information about clinical research sites for patients with PCD is available at:",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://rarediseasesnetwork.epi.usf.edu/gdmcc/learnmore/index.htm\">",
"     file://rarediseasesnetwork.epi.usf.edu/gdmcc/learnmore/index.htm#pcd",
"    </a>",
"   </p>",
"   <p>",
"    Additional information for patients and families can be found on the PCD Foundation website at:",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.pcdfoundation.org/\">",
"     file://www.pcdfoundation.org/",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26740158\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary ciliary dyskinesia, also called the immotile-cilia syndrome, includes patients with a spectrum of ciliary abnormalities, including ciliary akinesia, dyskinesia and aplasia. It is characterized by chronic cough, bronchiectasis, chronic rhinitis, and chronic sinusitis. (See",
"      <a class=\"local\" href=\"#H26740018\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The inheritance pattern is autosomal recessive. Linkage studies have identified a locus on chromosome 5p encoding an axonemal dynein heavy chain protein called DNAH5. Situs inversus is present in about 50 percent of individuals. (See",
"      <a class=\"local\" href=\"#H26740025\">",
"       'Genetics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26740032\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measuring concentration of exhaled nasal nitric oxide (nNO) is a useful method to screen patients with a clinical suspicion of PCD. Alternative screening tests of ciliary function include inhalation aerosol of colloid albumin tagged with 99Tc and saccharin clearance time. None of these is diagnostic and must be followed by a confirmatory test. (See",
"      <a class=\"local\" href=\"#H26740088\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive diagnosis is based on electron microscopic visualization of specific defects, such as absence of dynein arms or radial spokes and absent, or additional, microtubule assemblies. High speed video microscopy in conjunction with beat frequency measurement can determine whether cilia have normal coordination, beat frequency, and beat pattern. (See",
"      <a class=\"local\" href=\"#H26740088\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic testing, although not usually part of the initial evaluation, is available for some of the mutations that cause PCD and may be diagnostic. (See",
"      <a class=\"local\" href=\"#H26740123\">",
"       'Genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persons with primary ciliary dyskinesia generally live an active life and have a normal lifespan. The rate of decline of lung function is much slower than that with cystic fibrosis. (See",
"      <a class=\"local\" href=\"#H26740144\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Smoking probably causes a more rapid deterioration in lung function, and counseling regarding smoking cessation is essential. (See",
"      <a class=\"local\" href=\"#H26740144\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interventions to improve secretion clearance and reduce respiratory infections include daily chest physiotherapy and prompt treatment of respiratory infections. The role of nebulized",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/13/29908?source=see_link\">",
"       DNase",
"      </a>",
"      and other mucolytic drugs is less clear. (See",
"      <a class=\"local\" href=\"#H26740144\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical interventions to treat middle ear disease, maxillary sinusitis, and nasal polyposis may be necessary in a subset of patients. (See",
"      <a class=\"local\" href=\"#H26740144\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bilateral lung transplantation is the therapy of choice in patients with end-stage respiratory insufficiency, although heart-lung transplantation or a modified surgical procedure is required in patients with situs inversus. (See",
"      <a class=\"local\" href=\"#H26740144\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because ciliary immotility (or dysmotility) is commonly associated with abnormal sperm motility, male patients should be informed about possible infertility, and semen analysis should be offered. In vitro fertilization techniques, particularly intracytoplasmic sperm injection, have been effective in this setting. (See",
"      <a class=\"local\" href=\"#H26740144\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/1\">",
"      Corkey CW, Levison H, Turner JA. The immotile cilia syndrome. A longitudinal survey. Am Rev Respir Dis 1981; 124:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/2\">",
"      Kollberg H, Mossberg B, Afzelius BA, et al. Cystic fibrosis compared with the immotile-cilia syndrome. A study of mucociliary clearance, ciliary ultrastructure, clinical picture and ventilatory function. Scand J Respir Dis 1978; 59:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/3\">",
"      Afzelius BA. A human syndrome caused by immotile cilia. Science 1976; 193:317.",
"     </a>",
"    </li>",
"    <li>",
"     Afzelius BA, Mossberg B, Bergstr&ouml;m SE. Immotile-cilia syndrome (primary ciliary dyskinesia) including Kartagener syndrome. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Vale D (Eds), McGraw Hill, New York 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/5\">",
"      Afzelius BA, Stenram U. Prevalence and genetics of immotile-cilia syndrome and left-handedness. Int J Dev Biol 2006; 50:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/6\">",
"      Nonaka S, Shiratori H, Saijoh Y, Hamada H. Determination of left-right patterning of the mouse embryo by artificial nodal flow. Nature 2002; 418:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/7\">",
"      Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004; 169:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/8\">",
"      Kuehni CE, Frischer T, Strippoli MP, et al. Factors influencing age at diagnosis of primary ciliary dyskinesia in European children. Eur Respir J 2010; 36:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/9\">",
"      Zariwala MA, Knowles MR, Omran H. Genetic defects in ciliary structure and function. Annu Rev Physiol 2007; 69:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/10\">",
"      Rosenbaum JL, Cole DG, Diener DR. Intraflagellar transport: the eyes have it. J Cell Biol 1999; 144:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/11\">",
"      Merveille AC, Davis EE, Becker-Heck A, et al. CCDC39 is required for assembly of inner dynein arms and the dynein regulatory complex and for normal ciliary motility in humans and dogs. Nat Genet 2011; 43:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/12\">",
"      Becker-Heck A, Zohn IE, Okabe N, et al. The coiled-coil domain containing protein CCDC40 is essential for motile cilia function and left-right axis formation. Nat Genet 2011; 43:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/13\">",
"      Mitchison HM, Schmidts M, Loges NT, et al. Mutations in axonemal dynein assembly factor DNAAF3 cause primary ciliary dyskinesia. Nat Genet 2012; 44:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/14\">",
"      Boon M, Jorissen M, Proesmans M, De Boeck K. Primary ciliary dyskinesia, an orphan disease. Eur J Pediatr 2013; 172:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/15\">",
"      Pennarun G, Escudier E, Chapelin C, et al. Loss-of-function mutations in a human gene related to Chlamydomonas reinhardtii dynein IC78 result in primary ciliary dyskinesia. Am J Hum Genet 1999; 65:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/16\">",
"      Olbrich H, H&auml;ffner K, Kispert A, et al. Mutations in DNAH5 cause primary ciliary dyskinesia and randomization of left-right asymmetry. Nat Genet 2002; 30:143.",
"     </a>",
"    </li>",
"    <li>",
"     Online Medelian Inheritance in Man (OMIM) file://www.ncbi.nlm.nih.gov/omim (Accessed on July 09, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/18\">",
"      Fliegauf M, Olbrich H, Horvath J, et al. Mislocalization of DNAH5 and DNAH9 in respiratory cells from patients with primary ciliary dyskinesia. Am J Respir Crit Care Med 2005; 171:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/19\">",
"      Morillas HN, Zariwala M, Knowles MR. Genetic causes of bronchiectasis: primary ciliary dyskinesia. Respiration 2007; 74:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/20\">",
"      Duriez B, Duquesnoy P, Escudier E, et al. A common variant in combination with a nonsense mutation in a member of the thioredoxin family causes primary ciliary dyskinesia. Proc Natl Acad Sci U S A 2007; 104:3336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/21\">",
"      Loges NT, Olbrich H, Fenske L, et al. DNAI2 mutations cause primary ciliary dyskinesia with defects in the outer dynein arm. Am J Hum Genet 2008; 83:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/22\">",
"      Schwabe GC, Hoffmann K, Loges NT, et al. Primary ciliary dyskinesia associated with normal axoneme ultrastructure is caused by DNAH11 mutations. Hum Mutat 2008; 29:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/23\">",
"      Castleman VH, Romio L, Chodhari R, et al. Mutations in radial spoke head protein genes RSPH9 and RSPH4A cause primary ciliary dyskinesia with central-microtubular-pair abnormalities. Am J Hum Genet 2009; 84:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/24\">",
"      Leigh MW, Zariwala MA, Knowles MR. Primary ciliary dyskinesia: improving the diagnostic approach. Curr Opin Pediatr 2009; 21:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/25\">",
"      Tan SY, Rosenthal J, Zhao XQ, et al. Heterotaxy and complex structural heart defects in a mutant mouse model of primary ciliary dyskinesia. J Clin Invest 2007; 117:3742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/26\">",
"      Noone PG, Bali D, Carson JL, et al. Discordant organ laterality in monozygotic twins with primary ciliary dyskinesia. Am J Med Genet 1999; 82:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/27\">",
"      Bush A, Cole P, Hariri M, et al. Primary ciliary dyskinesia: diagnosis and standards of care. Eur Respir J 1998; 12:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/28\">",
"      Lie H, Ferkol T. Primary ciliary dyskinesia: recent advances in pathogenesis, diagnosis and treatment. Drugs 2007; 67:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/29\">",
"      Lie H, Zariwala MA, Helms C, et al. Primary ciliary dyskinesia in Amish communities. J Pediatr 2010; 156:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/30\">",
"      Chapelin C, Coste A, Reinert P, et al. Incidence of primary ciliary dyskinesia in children with recurrent respiratory diseases. Ann Otol Rhinol Laryngol 1997; 106:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/31\">",
"      Santamaria F, Montella S, Tiddens HA, et al. Structural and functional lung disease in primary ciliary dyskinesia. Chest 2008; 134:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/32\">",
"      Nadel HR, Stringer DA, Levison H, et al. The immotile cilia syndrome: radiological manifestations. Radiology 1985; 154:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/33\">",
"      Kennedy MP, Noone PG, Leigh MW, et al. High-resolution CT of patients with primary ciliary dyskinesia. AJR Am J Roentgenol 2007; 188:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/34\">",
"      Homma S, Kawabata M, Kishi K, et al. Bronchiolitis in Kartagener's syndrome. Eur Respir J 1999; 14:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/35\">",
"      Marthin JK, Petersen N, Skovgaard LT, Nielsen KG. Lung function in patients with primary ciliary dyskinesia: a cross-sectional and 3-decade longitudinal study. Am J Respir Crit Care Med 2010; 181:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/36\">",
"      Pifferi M, Bush A, Caramella D, et al. Agenesis of paranasal sinuses and nasal nitric oxide in primary ciliary dyskinesia. Eur Respir J 2011; 37:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/37\">",
"      Pruli&egrave;re-Escabasse V, Coste A, Chauvin P, et al. Otologic features in children with primary ciliary dyskinesia. Arch Otolaryngol Head Neck Surg 2010; 136:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/38\">",
"      Majithia A, Fong J, Hariri M, Harcourt J. Hearing outcomes in children with primary ciliary dyskinesia--a longitudinal study. Int J Pediatr Otorhinolaryngol 2005; 69:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/39\">",
"      TORGERSEN J. Transposition of viscera, bronchiectasis and nasal polyps; a genetical analysis and a contribution to the problem of constitution. Acta radiol 1947; 28:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/40\">",
"      Greenstone MA, Jones RW, Dewar A, et al. Hydrocephalus and primary ciliary dyskinesia. Arch Dis Child 1984; 59:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/41\">",
"      Picco P, Leveratto L, Cama A, et al. Immotile cilia syndrome associated with hydrocephalus and precocious puberty: a case report. Eur J Pediatr Surg 1993; 3 Suppl 1:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/42\">",
"      De Santi MM, Magni A, Valletta EA, et al. Hydrocephalus, bronchiectasis, and ciliary aplasia. Arch Dis Child 1990; 65:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/43\">",
"      Jonsson MS, McCormick JR, Gillies CG, Gondos B. Kartagener's syndrome with motile spermatozoa. N Engl J Med 1982; 307:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/44\">",
"      Greenstone M, Rutman A, Dewar A, et al. Primary ciliary dyskinesia: cytological and clinical features. Q J Med 1988; 67:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/45\">",
"      Kennedy MP, Omran H, Leigh MW, et al. Congenital heart disease and other heterotaxic defects in a large cohort of patients with primary ciliary dyskinesia. Circulation 2007; 115:2814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/46\">",
"      Raman R, Al-Ali SY, Poole CA, et al. Isomerism of the right atrial appendages: clinical, anatomical, and microscopic study of a long-surviving case with asplenia and ciliary abnormalities. Clin Anat 2003; 16:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/47\">",
"      Barbato A, Frischer T, Kuehni CE, et al. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. Eur Respir J 2009; 34:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/48\">",
"      Corbelli R, Bringolf-Isler B, Amacher A, et al. Nasal nitric oxide measurements to screen children for primary ciliary dyskinesia. Chest 2004; 126:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/49\">",
"      Grasemann H, G&auml;rtig SS, Wiesemann HG, et al. Effect of L-arginine infusion on airway NO in cystic fibrosis and primary ciliary dyskinesia syndrome. Eur Respir J 1999; 13:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/50\">",
"      Horv&aacute;th I, Loukides S, Wodehouse T, et al. Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia. Thorax 2003; 58:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/51\">",
"      Karadag B, James AJ, G&uuml;ltekin E, et al. Nasal and lower airway level of nitric oxide in children with primary ciliary dyskinesia. Eur Respir J 1999; 13:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/52\">",
"      Marthin JK, Nielsen KG. Choice of nasal nitric oxide technique as first-line test for primary ciliary dyskinesia. Eur Respir J 2011; 37:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/53\">",
"      Csoma Z, Bush A, Wilson NM, et al. Nitric oxide metabolites are not reduced in exhaled breath condensate of patients with primary ciliary dyskinesia. Chest 2003; 124:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/54\">",
"      Narang I, Ersu R, Wilson NM, Bush A. Nitric oxide in chronic airway inflammation in children: diagnostic use and pathophysiological significance. Thorax 2002; 57:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/55\">",
"      Pifferi M, Caramella D, Cangiotti AM, et al. Nasal nitric oxide in atypical primary ciliary dyskinesia. Chest 2007; 131:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/56\">",
"      Pifferi M, Bush A, Maggi F, et al. Nasal nitric oxide and nitric oxide synthase expression in primary ciliary dyskinesia. Eur Respir J 2011; 37:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/57\">",
"      Camner P, Mossberg B, Afzelius BA. Measurements of tracheobronchial clearance in patients with immotile-cilia syndrome and its value in differential diagnosis. Eur J Respir Dis Suppl 1983; 127:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/58\">",
"      Marthin JK, Mortensen J, Pressler T, Nielsen KG. Pulmonary radioaerosol mucociliary clearance in diagnosis of primary ciliary dyskinesia. Chest 2007; 132:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/59\">",
"      De Boeck K, Proesmans M, Mortelmans L, et al. Mucociliary transport using 99mTc-albumin colloid: a reliable screening test for primary ciliary dyskinesia. Thorax 2005; 60:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/60\">",
"      K&auml;rj&auml; J, Nuutinen J. Immotile cilia syndrome in children. Int J Pediatr Otorhinolaryngol 1983; 5:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/61\">",
"      Chilvers MA, Rutman A, O'Callaghan C. Functional analysis of cilia and ciliated epithelial ultrastructure in healthy children and young adults. Thorax 2003; 58:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/62\">",
"      Stannard WA, Chilvers MA, Rutman AR, et al. Diagnostic testing of patients suspected of primary ciliary dyskinesia. Am J Respir Crit Care Med 2010; 181:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/63\">",
"      Afzelius BA. The immotile-cilia syndrome: a microtubule-associated defect. CRC Crit Rev Biochem 1985; 19:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/64\">",
"      Stannard W, Rutman A, Wallis C, O'Callaghan C. Central microtubular agenesis causing primary ciliary dyskinesia. Am J Respir Crit Care Med 2004; 169:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/65\">",
"      Escudier E, Couprie M, Duriez B, et al. Computer-assisted analysis helps detect inner dynein arm abnormalities. Am J Respir Crit Care Med 2002; 166:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/66\">",
"      Jorissen M, Willems T, Van der Schueren B, et al. Ultrastructural expression of primary ciliary dyskinesia after ciliogenesis in culture. Acta Otorhinolaryngol Belg 2000; 54:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/67\">",
"      Hirst RA, Rutman A, Williams G, O'Callaghan C. Ciliated air-liquid cultures as an aid to diagnostic testing of primary ciliary dyskinesia. Chest 2010; 138:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/68\">",
"      Mencarelli C, Tiezzi A, Ruggiero P, et al. Heterogeneous localization of epitopes along axonemes of mammalian cilia. Biol Cell 1995; 83:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/69\">",
"      Kastury K, Taylor WE, Shen R, et al. Complementary deoxyribonucleic acid cloning and characterization of a putative human axonemal dynein light chain gene. J Clin Endocrinol Metab 1997; 82:3047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/70\">",
"      Maglione M, Bush A, Montella S, et al. Progression of lung disease in primary ciliary dyskinesia: is spirometry less accurate than CT? Pediatr Pulmonol 2012; 47:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/71\">",
"      Ellerman A, Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. Eur Respir J 1997; 10:2376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/72\">",
"      ten Berge M, Brinkhorst G, Kroon AA, de Jongste JC. DNase treatment in primary ciliary dyskinesia--assessment by nocturnal pulse oximetry. Pediatr Pulmonol 1999; 27:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/73\">",
"      Stafanger G, Garne S, Howitz P, et al. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J 1988; 1:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/74\">",
"      Smit HJ, Schreurs AJ, Van den Bosch JM, Westermann CJ. Is resection of bronchiectasis beneficial in patients with primary ciliary dyskinesia? Chest 1996; 109:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/75\">",
"      Mossberg B, Afzelius B, Camner P. Mucociliary clearance in obstructive lung diseases. Correlations to the immotile cilia syndrome. Eur J Respir Dis Suppl 1986; 146:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/76\">",
"      Tkebuchava T, Niederh&auml;user U, Weder W, et al. Kartagener's syndrome: clinical presentation and cardiosurgical aspects. Ann Thorac Surg 1996; 62:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/77\">",
"      Miralles A, Muneretto C, Gandjbakhch I, et al. Heart-lung transplantation in situs inversus. A case report in a patient with Kartagener's syndrome. J Thorac Cardiovasc Surg 1992; 103:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/37/9817/abstract/78\">",
"      von Zumbusch A, Fiedler K, Mayerhofer A, et al. Birth of healthy children after intracytoplasmic sperm injection in two couples with male Kartagener's syndrome. Fertil Steril 1998; 70:643.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4338 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-5969107613-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_37_9817=[""].join("\n");
var outline_f9_37_9817=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26740158\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26740018\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26740025\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26740032\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26740039\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26740046\">",
"      Rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26740053\">",
"      Otitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26740060\">",
"      Situs inversus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26740067\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26740074\">",
"      Fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26740081\">",
"      Associated abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26740088\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26740095\">",
"      Nasal nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26740102\">",
"      Measures of mucociliary clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26740109\">",
"      Nasal and bronchial brushing/biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26740116\">",
"      Cell culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26740123\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26740130\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26740137\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26740144\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26740151\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26814682\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26740158\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4338\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4338|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/57/5008\" title=\"diagnostic image 1A\">",
"      Primary ciliary dyskinesia CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/19/43327\" title=\"diagnostic image 1B\">",
"      Primary ciliary dyskinesia PA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4338|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/8/14466\" title=\"figure 1\">",
"      Normal human axoneme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4338|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/43/24241\" title=\"picture 1A\">",
"      Primary ciliary dyskinesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/3/22576\" title=\"picture 1B\">",
"      Normal ciliary structure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4338|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/59/5052\" title=\"table 1\">",
"      Diagnostic tests for PCD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=related_link\">",
"      Acute otitis media in adults (suppurative and serous)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44662?source=related_link\">",
"      Clinical manifestations and evaluation of bronchiectasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=related_link\">",
"      Evaluation of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7416?source=related_link\">",
"      Exhaled nitric oxide analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/6/99?source=related_link\">",
"      Heart-lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26537?source=related_link\">",
"      Microbiology and antibiotic management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=related_link\">",
"      Treatment of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_37_9818="Desmoglein compensation theory";
var content_f9_37_9818=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Desmoglein compensation theory",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 669px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Graphic depiction of the desmoglein compensation theory. The&nbsp;desmoglein compensation theory is a proposed explanation for the&nbsp;correlation between the clinical features of pemphigus vulgaris and&nbsp; pemphigus foliaceus and the autoantibody profiles of these&nbsp;disorders. In the skin, desmoglein 1 (Dsg1) is expressed mostly in&nbsp;the upper portions of the epidermis, while desmoglein 3 (Dsg3) is&nbsp;expressed mostly in the basal and suprabasal layers of the&nbsp;epithelium. In the mucous membranes, Dsg3 is present in abundance&nbsp;throughout the epithelium, while Dsg1 is expressed to a much lower&nbsp;degree. Mucosal dominant pemphigus vulgaris (A) is characterized by&nbsp;autoantibodies against Dsg 3 and results in only mucosal lesions&nbsp;because Dsg1 compensates for the loss of Dsg3 in the skin. In the&nbsp;mucous membranes, Dsg1 cannot compensate resulting in&nbsp;intraepithelial blistering. In mucocutaneous pemphigus vulgaris&nbsp;(B), autoantibodies against both Dsg1 and Dsg3 are present. Thus, compensation occurs neither in the skin nor the mucous membranes,&nbsp;and blistering occurs in both locations. Pemphigus foliaceus (C) is&nbsp;characterized by autoantibodies against only Dsg1. This results in&nbsp;very superficial blisters in the skin. The mucous membranes are&nbsp;spared due to high levels of Dsg3 expression throughout the&nbsp;epithelium and low levels of Dsg1 expression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_37_9818=[""].join("\n");
var outline_f9_37_9818=null;
var title_f9_37_9819="NCCN rec mCRC nonintens";
var content_f9_37_9819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment options for patients with metastatic colorectal cancer who are not appropriate candidates for intensive therapy, according to NCCN guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Initial therapy",
"      </td>",
"      <td class=\"subtitle1\">",
"       Improved functional status",
"      </td>",
"      <td class=\"subtitle1\">",
"       No improved functional status",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Capecitabine &plusmn; bevacizumab",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Infusional 5-FU + leucovorin &plusmn; bevacizumab",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Cetuximab (WT Kras only)",
"       </p>",
"      </td>",
"      <td>",
"       Consider aggressive therapy, such as FOLFOX or FOLFIRI",
"      </td>",
"      <td>",
"       Best supportive care",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FOLFIRI: irinotecan plus short-term infusional 5-FU with leucovorin; FOLFOX: oxaplatin plus short-term infusional 5-FU with leucovorin; WT Kras: wild-type Kras in tumor tissue; NCCN: National Comprehensive Cancer Network.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_37_9819=[""].join("\n");
var outline_f9_37_9819=null;
var title_f9_37_9820="Erythema multiforme causes";
var content_f9_37_9820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of erythema multiforme",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Infectious causes of erythema multiforme",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Herpes simplex virus (most common)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Mycoplasma pneumoniae",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Parapoxvirus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Varicella zoster virus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Adenovirus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Epstein-Barr virus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cytomegalovirus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Viral hepatitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Coxsackie virus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Parvovirus B19",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Human immunodeficiency virus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chlamydophila psittaci",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Salmonella",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Mycobacterium tuberculosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Histoplasma capsulatum",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Dermatophytes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Others",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Medications associated with erythema multiforme",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          NSAIDs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfonamides",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Antiepileptics",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Antibiotics",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Others",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: Bolognia, JL, Jorizzo, JL, Rapini, RP. Dermatology, 2nd ed, Elsevier 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_37_9820=[""].join("\n");
var outline_f9_37_9820=null;
var title_f9_37_9821="Steady state sodium balance";
var content_f9_37_9821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Response to changes in sodium intake",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 230px; height: 175px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of abrupt changes in Na+ intake on body weight and renal Na+ excretion in a normal human. The shaded areas refer to changes in total body Na+ stores due to the difference between intake and excretion. See text for details.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Earley, LE, In: Clinical Disorders of Fluid and Electrolyte Metabolism, Maxwell, MH, Kleeman, CR (Eds), McGraw-Hill, New York, 1972.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_37_9821=[""].join("\n");
var outline_f9_37_9821=null;
var title_f9_37_9822="ECG abnormalities outcome";
var content_f9_37_9822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abnormalities on baseline ECG predict outcome in asymptomatic persons",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 305px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 4797 men and 4320 women, age 25 to 74 years, who were initially free of angina, 8.4 percent of men and 10.6 percent of women had ischemic ECG changes, including abnormal Q waves, varying degrees of ST depression or T wave inversion, and left bundle branch block. The presence of ischemic ECG changes, particularly ST depression and T-wave inversion, were associated with increased cardiovascular mortality in both men and women (multivariately adjusted odds ratio 2.45 and 2.16, respectively).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: De Bacquer D, De Backer G, Kornitzer M, et al. J Am Coll Cardiol 1998; 32:680.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_37_9822=[""].join("\n");
var outline_f9_37_9822=null;
var title_f9_37_9823="Knee jerk hyperreflexia in ALS";
var content_f9_37_9823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/NEURO/50755/alsknrfl_conv.mp4?title=Knee+jerk+hyperreflexia+in+ALS\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Knee jerk hyperreflexia in a patient with amyotrophic lateral sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An upper motor neuron sign, hyperreflexia is noted with testing deep tendon reflexes at the knees.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nestor Galvez- Jimenez, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_37_9823=[""].join("\n");
var outline_f9_37_9823=null;
